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Abstract 
Genetic changes acquired in the pigment producing cells of the skin, called 
melanocytes, can lead to formation of the deadly cancer melanoma. Mutations or 
amplifications leading to the activation of the RAS/MAPK pathway occur in more 
than 90% of melanomas. Melanocyte development and survival requires the 
stimulation of this pathway by the receptor tyrosine kinase (RTK) KIT. In ~2% of 
melanomas, oncogenic KIT mutations drive tumor formation; however, the 
majority of melanomas lose wild-type KIT expression, suggesting that KIT could 
suppress melanoma formation. In human melanoma patients of The Cancer 
Genome Atlas (TCGA), we found an association between BRAFV600E mutations 
and low KIT mRNA expression, so we tested whether KIT loss would affect 
BRAFV600E-driven tumor onset by crossing a kit(lf) mutant allele into melanoma-
prone Tg(mitfa:BRAFV600E); p53(lf) zebrafish. We observed that kit(lf)-mutant 
zebrafish experienced accelerated tumor onset and their tumors had increased 
RAS/MAPK pathway activation. In BRAFV600E-mutant melanoma cells, KIT 
activity reduced RAS/MAPK signaling by promoting activation of wild-type BRAF 
(BRAFWT). Furthermore, we found that overexpression of BRAFWT delayed tumor 
onset in Tg(mitfa:BRAFV600E); p53(lf); mitfa(lf) zebrafish, but had no effect in 
kit(lf); Tg(mitfa:BRAFV600E); p53(lf); mtifa(lf) zebrafish and a cohort of TCGA 
BRAFV600E-mutant melanoma patients with high KIT expression and high 
BRAFWT allele ratios experienced a reduced likelihood of metastasis and 
extended overall survival. These studies indicate that wild-type KIT acts to 
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suppress melanoma formation through activation of BRAFWT, causing reduced 
signaling output of BRAFV600E-mutant cells.  
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Chapter I - Introduction to KIT and RAS/MAPK pathway signaling in 
melanocytes and melanoma 
Genetic aberrations lead to cancer formation 
To survive, every multicellular organism must coordinate the growth of its cells. 
This coordination can be achieved through cellular communication and by 
following developmental and degenerative programs. If a cell goes rogue by 
following its own growth program, it may grow and multiply without limit forming 
masses of tissue and leading to the potentially fatal disease called cancer. Thus, 
to receive growth stimulatory or inhibitory signals from their environment, cells 
utilize a variety of mechanisms to communicate, including expression of surface 
receptors that recognize molecules emitted from other cells in their environment. 
These receptors transmit the signal into a cell by sparking a cascade of signaling 
activity that results in altered gene expression, causing a cell to grow, divide, 
differentiate, or die (2). The transmission of signal is typically achieved by protein 
enzymes called kinases, which communicate an activation signal by adding a 
phosphate group to a target protein leading to structural changes and new 
functions of that target protein. Kinases are among the largest groups of 
eukaryotic protein families and are well conserved across all of the multi-cellular 
metazoans (3,4).  
 
Internal programs also help regulate cellular lifecycles where proteins that 
sense DNA damage or a change in telomere length due to multiple cellular 
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divisions can also enact genetic expression programs to respond to these issues 
with slowed growth or death (5,6). As cells successfully grow and divide, genetic 
changes such as copy number alterations or mutations can accumulate due to 
genome replication errors and exposure to mutagens such as ultraviolet light 
(7,8). When these changes affect the structure or expression of the critical 
regulatory signaling genes, uncontrolled cellular growth can occur leading to 
formation of tumors (9).  
 
Genes that promote cancer formation due to an increase in function that 
resulted from a genetic alteration are referred to as oncogenes, whereas genes 
whose loss of function promotes cancer formation are referred to as tumor 
suppressors. Oncogenes are often discovered by identification of recurrent, 
disease-associated mutations or increases in expression of the aforementioned 
growth regulatory signal transduction genes. These mutations or increases in 
expression level can cause the proteins from these genes to function 
constitutively and independently, without upstream pathway stimulation. These 
proteins will then persistently drive the growth and survival transcriptional 
programs that normally would have required initiation from an external signal. For 
example, the product of the ABL gene on chromosome 9 functions as a tyrosine 
kinase to promote cellular growth and division, but a translocation with the BCR 
gene on chromosome 22 results in a constitutively active fusion product that acts 
constitutively and drives the formation of acute lymphocytic leukemia and chronic 
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myelogenous leukemia (10,11). Tumor suppressors are often negative regulators 
of growth stimulating pathways, such as NF1 or PTEN (12,13), or proteins that 
slow down the cell cycle or promote programed cell death such as RB or p53 (5).  
 
Oncogenes and tumor suppressor genes differ in the fate of their 
corresponding wild-type gene. A gain-of-function mutation in a single copy of an 
oncogene can drive tumor formation while leaving the wild-type allele intact, such 
as with the BRAFV600E mutant allele, which maintains heterozygosity in roughly 
two-thirds of melanomas, though the mutant allele has been shown to be 
preferentially amplified (14,15). Similarly, several tumor suppressor genes only 
require the loss of one allele to no longer be capable of inhibiting aberrant 
proliferation, such as PTEN, p27, and NF1 (16). On the other hand, losses of 
both copies of a genehave been observed at high frequencies for many tumor 
suppressor genes including  RB, BRCA1/2, APC, and CDKN2A; such an 
occurrence is referred to as a loss of heterozygosity (17-21). The requirement for 
losing one or both copies of a tumor suppressor gene may be context dependent. 
Indeed, an analysis of tumors from Li-Fraumeni patients showed that slightly less 
than half had lost the wild-type copy of their TP53 allele, yet clearly many tumors 
were able to form with a single germline mutation in TP53 (22). The form of 
ocular cancer retinoblastoma that is recessively inherited has been linked to the 
loss of both copies of the gene for the cell cycle inhibitor RB (23-25). The 
requirement for a loss of both copies of this gene for disease progression 
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provides a clear explanation for the observation that children with the inheritable 
form of this disease are more likely to develop bilateral retinoblastomas, as they 
would have been born with one defective copy of RB and require only two 
sporadic genetic mutation events to develop the disease in both eyes. However, 
children who had sporadic (non-inheritable) mutations are more likely to only 
develop unilateral disease. These observations led to the formation of the “two-
hit hypothesis” stating that cells require multiple genetic “hits” that alter their 
growth in order to become tumorigenic (26). Since this was proposed, it has been 
clear that the function and impact of mutations must be interpreted in the context 
of their genetic background.  
 
 Correct classification of the genetic contributions from mutant genes to 
cancer formation has become essential to understanding how cancer forms and 
for the development of targeted therapies. The identification of the BCR-ABL 
translocation allowed development of a small molecule inhibitor, imatinib, which 
blocks ATP-binding pocket to inhibit the kinase activity of BCR-ABL and other 
tyrosine kinases to effectively treat leukemia treatment (11). Cancer sequencing 
studies have revealed a vast number of genetic changes that occur during 
tumorigenesis. The loci of mutated oncogenes tend to be amplified with multiple 
copy numbers, while the loci of tumor suppressors are deleted (14,27). Although 
researchers have been able to identify new “driver genes” of cancer formation by 
introducing the mutations found in patients into normal cell types and observing a 
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transformative change (28), there are some genes that are recurrently amplified, 
deleted, or mutated in cancer, but have no impact on disease progression 
referred to as “passenger genes” (29). These passengers may have been 
amplified or deleted due to their proximity to a driver gene, or recurrently mutated 
due to age or exposure to mutagens. Any gene identified to be frequently altered 
in cancer must be tested to determine whether its change was a cause or 
consequence of tumorigenesis. Therefore, determining true cancer-causing 
genes and searching to understand how they work under various genetic 
contexts represents a major current challenge in cancer biology.  
 
Melanoma is a deadly cancer of melanocytes 
One of the most perplexing cancers to sort through its many genetic changes is 
melanoma, the deadly cancer of the pigment producing cells called melanocytes. 
Melanocytes reside in the basal layer of the human epidermis, originating from 
stem cells located in the bulge region of hair follicles (30). These cells produce 
the pigment melanin in the form of dark brown eumelanin and reddish-colored 
pheomelanin, which is shipped to neighboring keratinocytes of the skin and 
establishes skin tone. Eumelanin helps to shield cells from harmful UV radiation 
(31-35). Radiation from sun exposure has potential to induce C->T mutations, but 
a degree of this radiation can be shielded from causing serious DNA damage 
with a sufficient level of melanin pigment (32,36). Indeed, higher amounts of skin 
pigmentation have been correlated with reduced UV-skin penetration and 
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reduced risk of developing melanoma (37,38), whereas increased UV exposure 
through the use of tanning beds has been linked with increased cancer risk (39). 
Despite a melanocyte’s production of pigment, over time it can still acquire both 
sun-induced and non-sun-induced mutations that cause uncontrolled cell growth.  
 
 Initially, a melanocyte that has acquired a tumorigenic mutation will 
multiply locally and form benign pigmented spots called nevi or moles. These 
cells have typically acquired a single mutation, but have become senescent and 
can be considered benign when they are small, have a smooth defined border 
and remain the same size over time (40,41). However, if a pigmented patch is 
asymmetric, has an irregular border, different colors or uneven structural 
components, and a diameter greater than 6 mm, it is possible the lesion has 
overcome senescence by acquiring additional genetic changes and would 
warrant histological testing to determine if it had become a melanoma (42). 
Although the number of nevi a person has correlates with their likelihood to get 
melanoma (43), it is unclear whether melanomas necessarily originate from nevi, 
or rather originate from melanocyte precursor cells or differentiated melanocytes. 
Once transformed, melanomas have been traditionally classified according to 
their growth relative to the epidermis where they may remain in place (melanoma 
in-situ), spread along the epidermis of the skin without invasion (superficial 
spreading melanoma), invade into subdermal tissues (vertical growth phase), or 
metastasize to distant locations (44). Melanoma tumor depth has been strongly 
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correlated with survival outcome. Melanomas with 1 to 2 mm of depth have a 
90% or 80% 10-year survival rate, respectively; whereas melanomas with 3 or >4 
mm of depth have 63% and 50% 10-year survival rates (45). The presence of 
regional lymph node or distant metastases further decreases 10-year 
survivorship rates to 10-20% (45). 
 
An analysis of the Surveillance, Epidemiology, and End Results (SEER) 
program data that tracked melanoma incidence and survival in the United States 
from 1982 to 2011 found that melanoma incidence doubled during that time 
period to a level of 19.7 cases per 100,000 people in 2011 (46). The same study 
found a steady death rate of 2.7 deaths per 100,000 people, which is expected to 
remain relatively constant for the next several decades (46). The increasing rate 
of melanoma incidence has been attributed to increased diagnosis of thin (<1 
mm) melanomas, while increased UV exposure may also be a contributing factor 
(47). Risk of melanoma is also associated with freckling, blonde or red hair, and 
blue eyes; each of which indicates deficiencies in eumelanin production (38).  
 
Survival rates for surgical removal of low stage (non-metastatic) 
melanomas are generally high with recurrence rates as low as 2.2% after 10 
years (48), but historical treatment options have had minimal survival benefit for 
metastatic melanoma patients. The standard treatment for advanced stage 
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melanoma has been with the DNA-alkylating agent dacarbazine, the only 
standard chemotherapeutic drug with FDA approval for melanoma. Dacarbazine 
efficacy has been modest. A representative phase III clinical trial of stage IV 
melanoma patients reported that the cohort treated with dacarbazine had a 
response rate of 9.8% and median overall survival of 9.1 months (49). Several 
decades of attempts to improve melanoma outcome with typical chemotherapy 
regimens yielded little improvement to survival, leaving a great medical need for 
better treatment options for this disease (49). As described below, hope for 
improved treatment began to emerge in the 2000s as sequencing studies 
revealed targetable mutations in melanoma and as scientists improved methods 
to activate the immune system in cancer treatment (50,51). Additional targeted 
therapies may be developed as the transcriptional signature of melanoma is 
further defined. Among the early observations of gene expression changes in 
melanoma is the observation that many tumors dedifferentiate and re-express 
neural crest genes (52,53). Many of these genes that play a role during 
melanocyte differentiation and maintenance also affect melanoma onset and 
progression; therefore, understanding the complexity of melanocyte development 
will be essential for describing melanoma biology. 
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Melanocyte development and differentiation in relation to melanoma 
formation 
The developmental history of melanocytes sheds light on the nature of 
melanoma progression. Melanocytes originate from the embryonic tissue called 
the neural crest that forms at the boundary between the ectoderm and the neural 
plate during formation of the neural tube (54). The neural crest cells are 
characterized by their highly migratory nature as they spread away from the 
neural tube and migrate throughout the embryo to form the peripheral and enteric 
neurons, glia, craniofacial cartilage and bone, smooth muscle, and melanocytes 
(54). The identification of the genes that guide melanocyte development from the 
neural crest, particularly for the critical factors PAX3, EDN3, EDNRB, SNAI2, 
SOX10 and MITF, was largely informed through experiments linking mutations in 
these genes to pigment defects in mice and to the disorder Waardenburg 
syndrome, a disease characterized by pigment defects, craniofacial defects, and 
hearing loss due to the absence of cochlear melanocytes (55-58). Prior to the 
expression of these factors, early BMP signaling is required for establishment of 
the neural crest during development (Fig. I.1) (59). For melanocytes to develop 
from the neural crest, BMP signaling must decrease while WNT signaling turns 
on and neural crest cells become migratory (60,61). Next, melanocyte precursor 
cells begin to express the transcription factor SOX10 at sufficient levels to 
promote expression of several critical differentiation factors, including the master 
regulator of melanocyte differentiation, microphthalmia-associated transcription 
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factor (MITF) (Fig. I.1) (62-64). MITF is a leucine-zipper transcription factor that 
promotes expression of genes downstream of E-boxes with the consensus 
sequence CA[C/T]GTG that play critical roles in defining melanocyte identity 
such as the pigment production genes TYR and DCT and genes involved in 
promoting melanocyte survival such as the anti-apoptotic factor BCL2 (65-67). 
The activity and expression level of MITF in melanocytes can be controlled with 
upstream activation of the MAPK pathway by stimulation of KIT (Fig. I.2) (68). 
Loss of KIT activity through mutation or deletion is also associated with a loss of 
pigment cells, demonstrating that this factor is critical for melanocyte 
development (69-72). Its role will be discussed more fully below. 
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Figure I.1 
 
Figure I.1 – Genetic regulators of melanocyte and melanoma development 
The neural crest is established through activation of BMP and SOX10 signaling. 
Further melanocyte development requires a loss of BMP activity, but a gain in 
WNT, KIT, and MITF expression resulting in expression of pigment production 
genes DCT and TYR. Acquisition of a BRAF or NRAS mutation may lead to 
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senescence and formation of benign nevi; however, secondary events including 
strong expression of neural crest genes, loss of tumor suppressors, and loss of 
KIT may lead to cell cycle progression and generation of melanoma. Modulation 
of MITF expression further influences melanoma growth making it more highly 
invasive or proliferative with low or high MITF expression, respectively.  
13 
 
 Experiments have shown that melanomas regain a transcriptional profile 
similar to their neural crest origins and less similar to the differentiated state of 
melanocytes (52,53). This involves high expression of neural crest genes and is 
thought to contribute to the ability of melanomas to become highly migratory and 
possess high plasticity, or the ability to switch phenotypes dependent on micro-
environmental contexts from highly proliferative to highly invasive forms (73,74). 
The neural crest identity of melanomas represents a potential target as a 
therapeutic approach for melanoma patients. Indeed clinical trials have begun 
evaluating inhibitors of DHODH, a transcription elongation factor that promotes 
the neural crest transcriptional program in melanoma (52).  
 
 A strong, but complicated link exists between specific melanocyte 
differentiation genes and melanoma progression. The primary facilitator of neural 
crest induction leading to melanocyte differentiation, SOX10, has been shown to 
play an oncogenic role in melanomas where it is overexpressed and drives 
proliferation (75). The link between MITF and melanoma is complex. Although 
MITF has been shown to be highly expressed in the majority of melanomas and 
its overexpression can transform a pre-malignant melanocyte cell type, 
abnormally low MITF activity levels can also be transforming (Fig. I.1) (76,77).  
This has led to the proposal of a rheostat model of MITF activity in melanoma 
where high expression levels are associated with a proliferative state with 
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enhanced survival through upregulation of BCL-2, whereas low expression levels 
are associated with increased invasiveness (67,73). Intriguingly, the 
transplantation of cells that had been sorted into groups based on markers for 
the “proliferative” or “invasive” signatures would grow to produce heterogeneous 
tumors, demonstrating that melanomas maintain an ability to adapt their 
transcriptional profiles to suit their environment and growth (74). The control of 
MITF activity and the activity of other melanocyte specification genes clearly 
plays an important role in melanoma biology and the determination of the 
tumorigenic effects of additional melanocyte development genes remains a vital 
area of research. 
 
MAPK pathway activation and regulation in melanoma 
The exterior signals that activate MITF to promote melanocyte differentiation are 
mediated through the RAS/MAPK pathway signaling cascade (Fig. I.2). This 
pathway is frequently hyperactivated in cancer and is central to melanoma 
progression, where activating mutations or other genetic alterations of this 
pathway are present in greater than 90% of human melanomas (78).  
 
 The role of this pathway is to interpret signals from outside the cell and 
transform that information into action within a cell to instruct it to grow and divide. 
This can happen when extracellular ligands bind to cell surface receptors on the 
extracellular side of a cell. This binding of ligand to receptor causes the receptor 
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to homodimerize and acquire a conformation that favors kinase activity leading to 
auto-phosphorylation of the tyrosine residues on the tail of the receptor (2). The 
phosphorylated tyrosine residues will be directly bound by the SH2 domains of 
GRB2 that will recruit the guanine nucleotide exchange factor SOS, which will 
switch GDP for GTP binding on the membrane-localized protein RAS, leading to 
its activation. In a resting state the RAF family members ARAF, BRAF, and 
CRAF exist as inactive monomers in the cytoplasm, but will relocate to the 
plasma membrane via an interaction with phosphatidic acid that forms as a result 
of mitogen-induced phospholipase D activity (79). This positions RAF at the 
membrane where it will undergo activation if its RAS-binding domain (RBD) is 
able to bind GTP-RAS (80-82). This binding causes RAF family members to 
undergo a conformational shift that favors dimerization. Although this 
dimerization can occur between any two RAF family members, the 
heterodimerization of BRAF with CRAF is the most predominant and active dimer 
pair (83). RAF proteins are serine kinases that require dimerization and 
phosphorylation of both their activation loops and their N-terminal acidic (NTA) 
domains to become active, in addition to several dephosphorylation events. The 
NTA of BRAF contains the amino acids SSDD from positions 446-449, imitating a 
constitutively phosphorylated state. Upon membrane recruitment BRAF will 
undergo a conformational change, receive several additional activating 
phosphorylations releasing its activation loop to free its kinase domain, and will 
proceed to dimerize and transactivate CRAF, which phosphorylates MEK on 
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serine residues (84). A scaffolding protein named kinase suppressor of RAS 
(KSR), which is similar in shape to the RAF family, helps facilitate the binding 
between BRAF and CRAF with MEK1 and MEK2 (referred to collectively as MEK 
in this manuscript) (85). Activated MEK goes on to phosphorylate the threonine 
and tyrosine residues of the activation loop on ERK1 or ERK2 (Map Kinase, 
collectively referred to as ERK in this manuscript) that enters the nucleus and 
phosphorylates and activates multiple substrates resulting in an increase in 
cellular growth and division (86). Furthermore ERK phosphorylates MITF on S73 
leading to its activation (68), though ERK activity also results in downstream 
activation of the serine/threonine kinase RSK-1 that tags MITF for proteasome-
mediated degradation with a phosphorylation at S409 (87). While these 
temporary bursts of MITF activity may be required for melanocyte development, it 
has been hypothesized that persistent KIT stimulation would result in reduced 
MITF expression and therefore inhibit the proliferation and survival of 
melanocytes (87). Therefore, precise control of the MAPK pathway is required to 
enable proper melanocyte development (Fig. I.2). 
 
 Multiple mechanisms exist within a cell to negatively regulate ERK activity 
if the extrinsic signal does not cease in a timely fashion. ERK activity leads to an 
increase in the expression levels of SPRY and DUSP genes, where the SPRY 
protein goes on to sequester GRB and SOS to prevent activation of RAS and 
DUSP will dephosphorylate the threonine and tyrosine residues on ERK (88). An 
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additional negative feedback loop occurs when ERK directly phosphorylates 
BRAF on residues S151, T401, S750, and T753, causing BRAF to poorly 
dimerize with CRAF and thus have reduced capacity to activate the MAPK 
pathway (89). 
  
Given the critical role BRAF plays in transmitting signals through the 
MAPK pathway that results in activation of MITF, it is not surprising that multiple 
sequencing studies have found BRAF to be the most mutated gene in cutaneous 
melanomas (28,78). The landmark study by Davies et. al in 2002 found that 
roughly 2/3rds of the melanoma samples they assayed possessed missense 
mutations in BRAF, and roughly half of those melanomas contained a valine to 
glutamic acid mutation at position 600 (BRAFV600E)(28). This mutation has been 
shown to increase the kinase activity of BRAF on its substrate MEK by 500-fold 
(90) and cause BRAF to have a 138-fold increased transforming capability in 
NIH-3T3 cells (28). A more recent sequencing study has confirmed the 
BRAFV600E mutation is the most common single mutation in melanoma, affecting 
roughly 40% of melanomas (78). The kinase domain of BRAF is typically held in 
an inactive conformation by a hydrophobic interaction within the kinase domain 
between the valine on position 600 in the activation segment and the p-loop. The 
V600E mutation disrupts this interaction by replacing that valine with a large, 
negatively charged glutamic acid residue, thought to mimic activating 
phosphorylations. This causes BRAF to enter an active conformation that can 
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phosphorylate MEK in the cytoplasm without upstream RAS activity (90). The 
high constitutive activity of BRAFV600E has been shown to be insensitive to the 
aforementioned negative feedback phosphorylations that occur on BRAF as a 
result of downstream ERK activity (89). BRAF mutations are thought to occur 
early in tumorigenesis, given that greater than 80% of benign nevi have been 
found to harbor this mutation (40). This indicates that BRAFV600E alone is 
insufficient to drive melanoma formation and that other factors must contribute to 
tumorigenesis. Due to the frequency and clear causative role in melanoma, 
BRAFV600E has been actively pursued as a therapeutic target. Small molecule 
inhibitors that can specifically fill the ATP-binding pocket of BRAFV600E to block its 
activity have been developed (91) and their use led to some degree of tumor 
regression in 81% of BRAFV600E-mutant melanoma patients; however, resistance 
to BRAFV600E inhibitors invariably develops over the course of several months 
(50). Resistance generally occurs through re-activation of the MAPK pathway 
and may occur intrinsically due to mechanisms such as stromal secretion of the 
MET-stimulating factor HGF (92), or resistance may be acquired through 
mechanisms such as BRAFV600E alternative splicing, MAP3K8 upregulation, MEK 
mutations, upregulation of the RTK PDGFRβ, or acquisition of activating 
mutations in upstream components such as NRAS or even in alternative 
pathways such as the PI3K-PTEN-AKT pathway (93-97). RAF inhibitors have 
also been found to paradoxically promote activation of wild-type BRAF (BRAFWT) 
due to their promotion of BRAF:CRAF heterodimer formation yielding 
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transactivation of CRAF to stimulate the MAPK pathway (98). These clinical trials 
and the pursuant basic research studies on resistance mechanisms underscore 
the importance of maintenance of MAPK pathway signaling strength to sustain 
melanoma growth. 
 
Role of KIT in melanocyte development and cancer 
The activation of the MAPK pathway plays a critical role in melanocyte 
differentiation by stimulating the activity of the melanocyte master regulator, 
MITF, and in melanoma formation to enhance cellular growth and division. 
Therefore, the role of the RTK KIT in melanoma has been of particular interest to 
researchers for decades due to its role activating the RAS/MAPK pathway to 
promote melanocyte development and its role as a proto-oncogene in several 
cancer types.  
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Figure I.2 
 
Figure I.2 – KIT functions as a receptor tyrosine kinase to promote 
melanocyte development 
The binding of KIT to its ligand, stem cell factor, will induce a homodimerization 
of KIT receptor molecules at the plasma membrane. This dimerization promotes 
an interface where KIT will auto-phosphorylate its tyrosine residues, which are 
then recognized as an activation signal by several downstream pathways. Most 
critical to the function of KIT in melanocytes are its promotion of PI3K/AKT 
signaling to promote cell survival and activation of NRAS GTPases that go on to 
promote BRAF/CRAF dimerization leading to MEK and ERK activation, referred 
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to as the MAP Kinase pathway (MAPK pathway). ERK further phosphorylates 
MITF, the master regulator of melanocyte development, on S73 leading to 
increased transcriptional activity, but ERK activity also promotes RSK-1 activity, 
which phosphorylates MITF on S409 leading to ubiquitin mediated degradation of 
MITF. Thus, KIT stimulation leads to a temporary burst in MITF activity that is 
thought to play a critical role in promoting melanocyte development and survival. 
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 In 1986, a gene was cloned from virus purified from a feline fibrosarcoma 
tumor and designated v-kit (99). The virus transformed feline embryonic 
fibroblasts and sequencing of the viral DNA revealed a gene containing 
homology to tyrosine-specific kinase oncogenes, such as v-fms (the viral 
oncogene orthologue of macrophage growth factor receptor CSF-1) and human 
epidermal growth factor receptor (99). Southern blotting the v-kit DNA against 
cat, mouse, or human DNA revealed a likely cellular counterpart for each 
species, designated c-kit or KIT, later identified to reside on human chromosome 
4 and encode a 976 amino acid protein product in humans (99,100).The KIT 
gene contained sequences encoding an extracellular domain, a transmembrane 
domain, and a split intracellular tyrosine kinase domain. The immunoprecipitated 
KIT protein was confirmed to possess intrinsic auto-phosphorylation activity on its 
own tyrosine residues (100). Shortly after this discovery, various alleles of the W 
locus on chromosome 5 in mice that are well-known for having hematopoietic 
defects and lack pigment cells were mapped to the mouse orthologue of KIT 
(69,101-103). Homozygous W locus mutant mice are almost all embryonic lethal 
due to severe macrocytic anemia, whereas heterozygous mutants are viable, 
fertile, and manifest white spots on their bellies, feet, and tail tips (103). As 
additional mutations and deletions of KIT were linked with pigment defects 
across many species, it became clear that this gene plays a conserved role in 
promoting normal melanocyte development, migration and survival (104-109). In 
humans, the pigmentation disorder piebaldism, which manifests similar 
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pigmentation spotting phenotypes with patches of skin that lack melanocytes, 
has also been linked to heterozygous KIT deletions and loss-of-function 
mutations (72,110). Furthermore, a mutation of the steel mutant mouse that has 
a similar phenotype to W locus mutants was also mapped to a gene determined 
mechanistically to be the KIT ligand stem cell factor (SCF) (111).  
 
A pigment defect-linked KIT mutation was found to cause a similar amino 
acid change in mice and humans that occurs near the ATP-binding pocket of the 
KIT kinase domain and abolishes auto-phosphorylation activity, establishing the 
importance of KIT signaling activation in melanocyte formation (69-72). The 
tyrosine residues that become phosphorylated upon ligand-induced homo-
dimerization of KIT become recognized by a variety of signaling intermediary 
proteins including PI3K, and GRB that, as with a typical RTK described above, 
leads to the activation of the RAS/MAPK pathway (Fig. I.2). The mechanistic link 
between KIT activity and melanocyte development was realized through work 
that identified MITF was phosphorylated and activated in response to KIT 
stimulation (68). Importantly, a MEK inhibitor blocked the MITF phosphorylation 
by KIT, suggesting that the signal was mediated through the MAPK pathway 
(68). It was further demonstrated that the MEK target ERK could directly 
phosphorylate MITF on serine 73, which increased MITF transcriptional activity 
on the promoter of tyrosinase, a melanocyte-specific MITF target gene (68). 
Furthermore, the heightened activity of MITF downstream of KIT activation 
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seems to be tempered by an additional phosphorylation of serine 409 on MITF 
that results from RSK-1 activity downstream of ERK, which tags MITF for 
proteasome-mediated degradation (87). This regulatory pattern of dual activation 
and degradation of this critical transcription factor provides a clear mechanistic 
connection between KIT and melanocyte development, but the role of KIT in 
cancer is somewhat more complicated. 
 
In rare cutaneous melanomas that occur on volar surfaces of skin or in 
mucosa, 15-25% of cases contain mutations or amplifications of KIT that drive 
tumorigenesis (112-114). Inappropriate activation of KIT leads to ligand-
independent, constitutive downstream ERK and AKT signaling (115,116). KIT-
mutant melanomas and gastrointestinal stromal tumors (GISTs), which possess 
similar KIT mutations, have shown clinical responses to imatinib and other 
tyrosine kinase inhibitors (117,118). Whereas volar and mucosal melanomas 
represent about 2% of all melanomas, the most common melanomas, 
representing 90% of all cases, are cutaneous melanomas that occur on 
intermittently or chronically sun-exposed areas of the skin (119). Paradoxically, 
KIT expression is either low or undetectable in this latter category of melanomas, 
which are primarily driven by either BRAF or NRAS activating mutations (120-
122). The loss of KIT expression has been attributed to frequent deletion or 
hypermethylation of the KIT locus in melanoma (27,123). While the loss of KIT in 
cutaneous melanomas is well documented, it remains unclear whether this loss 
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is a cause or consequence of tumorigenesis. Although previous work in cultured 
cells has suggested that KIT activity may impede melanoma progression by 
promoting apoptosis or restricting migration (124-126), the impact of KIT activity 
on tumor initiation and oncogenic signaling in melanoma has yet to be explored. 
 
Zebrafish as a model for melanocyte and melanoma biology 
Manipulating a gene’s expression in an animal model of tumor development can 
test its contribution to tumor initiation. The zebrafish is an outstanding model to 
study melanocyte and melanoma biology for several reasons.  
 
First, the development of melanocytes from the neural crest is conserved 
between zebrafish and humans with many homologous genes determining 
control of melanocyte development including SOX10 and MITF, named sox10 
and mitfa in zebrafish (127,128). kit loss-of-function mutants (kit(lf)) have been 
identified among zebrafish and they also present reduced numbers of pigment 
cells; however, unlike mice, kit(lf) homozygous animals are viable and still 
develop some melanocytes (129,130). The primary kit(lf) mutant line in zebrafish 
was generated by gamma-irradiation and the sparse(b5) allele strain was found 
to contain a frame-shift mutation (T846del) in the gene kita, referred to as kit(lf) in 
this text, that results in an early stop allele and a protein product that lacks the 
transmembrane and kinase domains (130-132). Melanocytes develop poorly in 
kit(lf) zebrafish larvae with reduced numbers and migration failure apparent at 3-
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5 days post fertilization (dpf) (129). Melanocytes are then completely absent until 
the juvenile stage at 3-4 weeks when melanocytes will populate the striped areas 
of the fish to approximately half the density of wild-type fish, but none form on the 
dorsal region (129). A further distinction between kit mutant zebrafish and KIT 
mutant mammals is that kit(lf) zebrafish also maintain normal hematopoiesis 
(130). This indicates that, although Kit plays an important role in zebrafish 
melanocyte development, additional compensatory mechanisms are likely to 
exist in kit homozygous mutants to permit a modest level of melanocyte and 
hematopoietic development. It is unlikely that kitb, the zebrafish ohnologue 
(paralogue that forms as a result of a whole-genome duplication (133)) of kita, 
compensates for this loss of melanocyte development due to the lack of kitb 
expression in the neural crest (134). The homologue of the MITF gene in fish, 
mitfa, is just as critical for melanocyte development in fish as in other animals. 
The ENU-induced nacre(w2) allele contains a single base substitution in the mitfa 
gene that results in an early stop codon and a truncated protein that lacks the 
basic helix-loop-helix leucine zipper domain required for DNA binding, referred to 
in this text as mitfa(lf), resulting in animals completely devoid of melanocytes 
(128).  
 
 Second, an autochthonous model of melanoma development has been 
previously established in zebrafish (135). In this model the human BRAFV600E 
oncogene is driven to express in melanocytes as a transgene under the mitfa 
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promoter. On its own in zebrafish, BRAFV600E causes formation of benign 
hyperpigmented spots with high melanocyte density, referred to as fish-nevi, or f-
nevi (135). This is similar to the effect of BRAFV600E causing formation of nevi in 
mammals. When the BRAFV600E transgene was introduced into a p53 loss-of-
function mutation background, p53(zdf1), referred to in this text as p53(lf), these 
zebrafish developed fully-penetrant melanomas with a median onset of 4 months 
(135). An adaptation of this model was created to facilitate testing of genetic 
candidates for their contribution to melanoma formation. In this system 
researchers inject a construct, called miniCoopR, that juxtaposes a mitfa 
minigene with a transgene of interest driven by the mitfa promoter into a 
Tg(mitfa:BRAFV600E); p53(lf); mitfa(lf) background (136). The mitfa(lf) mutation 
prevents melanocyte formation, thus suppressing melanoma in the 
Tg(mitfa:BRAFV600E); p53(lf) background; however, injection of a miniCoopR 
construct with Tol2 transposase RNA into fertilized single-cell embryos will 
rescue melanocyte development in adult zebrafish and those melanocytes will go 
on to form melanomas that overexpress the candidate gene. This system was 
used to interrogate the overexpressed genes located in the human 1q21 region 
that is recurrently amplified in human melanoma and found that expression of the 
histone-methyltransferase SETDB1 significantly accelerated tumor onset 
compared to expression of EGFP (136). This illustrates several of the major 
advantages for using fish to study melanoma, namely their relative ease of 
genetic manipulation, their high fecundity (a single mating pair may produce 
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several hundred offspring per week, several thousand transgenic animals can be 
injected per week), and their visible melanoma onset. The use of the miniCoopR 
system provides a straightforward approach to testing candidate genes for their 
impact on autochthonous tumor development.  
 
 As with any model organism, several drawbacks exist when working with 
zebrafish that should be considered when planning and interpreting experiments. 
The zebrafish lineage underwent a whole genome duplication event resulting in 
many genes having duplicate copies that have diverged in function (137,138). 
Thus, when identifying a gene to inhibit, it is necessary to justify that the 
appropriate copy of the gene is being targeted and whether the sister ohnologue 
will have any compensatory function. Additionally, zebrafish require a generation 
time of at least three months, thus they require extensive time periods for 
generation of stable transgenic lines. Melanoma onset also requires 6-12 months 
to complete analysis for any given test population, therefore experiments must be 
carefully planned to account for these time-scales. 
 
 Additionally, it should be noted that the melanomas from 
Tg(mitfa:BRAFV600E); p53(lf) fish can grow exophytically or become locally 
invasive, but have not been confirmed to independently form distant metastases 
as seen in human melanomas (135). Nevertheless, a working model of 
melanoma metastasis has been established by subcutaneous transplantation of 
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zebrafish melanoma cell lines into irradiated, transparent casper mutant 
zebrafish (139) that have been shown to form lesions at sites distant and distinct 
from their injection sites (140). This quantifiable model of melanoma metastasis 
has been used to screen zebrafish larvae for modifiers of metastasis and found 
that the ligand of the G protein-coupled receptor EDNRB, EDN3, which is 
associated with Waardenburg syndrome and is required for melanocyte 
development, could induce a proliferation and differentiation of melanoma cells 
and enhanced metastatic spreading (141). It is anticipated that this method of 
transplanting zebrafish melanoma cell lines will continue to illuminate the 
processes involved in late stages of melanoma metastasis. Another contrast 
between zebrafish melanomas and human melanomas is in their mutation 
burden. Zebrafish melanomas contain a median of 4 coding mutations per 
zebrafish tumor, compared to 171 per sun-exposed human melanoma (142). 
Despite this difference, zebrafish melanomas are riddled with a high number of 
genomic rearrangements and copy number changes, similar to human 
melanomas (142). Researchers utilizing zebrafish should also consider the 
reported high heterogeneity of zebrafish melanomas and plan to use a 
sufficiently high sample size to give satisfactory statistical power for any tumor 
phenotype under evaluation (142). Despite these several items that must be 
considered during experimental planning, the high fecundity and ease of genetic 
manipulation of the zebrafish make it possible to evaluate a high number of 
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candidate genes with large sample sizes to test their contribution to genuine 
melanoma development. 
 
Rationale and objectives 
Although KIT has been defined as an oncogene in rare acral, mucosal, or in 
BRAF/NRAS/NF-1 wild-type melanomas, the aim of this work has been to clarify 
the role of KIT in the more common BRAF-mutant melanomas. Given that this 
large fraction of human melanomas, roughly 40% of cases, frequently loses KIT 
expression, it may be expected that the loss of KIT benefits BRAFV600E-driven 
tumor formation in some way; however, given the role of KIT in stimulating the 
RAS/MAPK pathway to promote melanocyte survival and migration, it appears 
counterintuitive to expect KIT to inhibit melanoma growth. It is possible that the 
loss of KIT is coincidental to melanoma progression; however, if KIT actively 
suppresses BRAFV600E-driven tumor onset, this discovery would help clarify the 
role of RTKs in RAF mutant cancers and suggest caution against targeting KIT in 
this class of melanomas. The zebrafish Tg(mitfa:BRAFV600E); p53(lf) melanoma 
model represents a working system to study the role of KIT, given the availability 
of the kit(lf) mutant line that may be crossed with Tg(mitfa:BRAFV600E); p53(lf) fish 
to determine the impact of KIT on melanoma development. 
The objectives for this project included: 
 To determine whether a meaningful association exists between the 
occurrence of BRAFV600E mutations and the loss of KIT expression in 
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human melanoma. This was carried out through analysis of The Cancer 
Genome Atlas Database that has published human melanoma RNAseq 
data for several hundred patient samples where mutation status and 
expression may be examined. 
 To test KIT loss in a zebrafish model of melanoma by crossing 
Tg(mitfa:BRAFV600E); p53(lf) with kit(lf) mutant zebrafish to generate kit(lf); 
Tg(mitfa:BRAFV600E); p53(lf) homozygous lines and compare melanoma 
onset, invasiveness, and Kit-pathway signaling. 
 To test the effect of KIT knockdown or overexpression in human 
melanoma cell lines. 
 To analyze the association of KIT expression with the clinical outcome of 
human melanoma patients.  
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Chapter II - KIT suppresses melanoma formation by attenuating BRAF 
oncogenic activity 
Preface 
Note that the contents of Chapter II have been adapted from the Student’s 
publication Neiswender et. al, Cancer Research 2017 (1). 
 
Introduction 
Key mutations that drive melanoma progression hyperactivate RAS/MAPK 
signaling (28,78). Activating mutations in BRAF and NRAS, the well-known 
drivers of MAPK pathway activity, are the most common oncogenic driver 
mutations in melanoma, found to occur in in 52% and 28% of the 318 samples 
published in the TCGA database (78). Loss-of-function mutations in the RAS-
GTP-ase activating protein NF1 prevent this protein from inhibiting RAS activity 
and thus lead to higher MAPK pathway activation in 14% of TCGA samples (78). 
At the top of this signaling cascade in melanocytes is the receptor tyrosine kinase 
KIT, known to play a critical role in melanocyte and hematopoietic development 
(69,101-103). Oncogenic mutations in KIT were found in only 6/318 (2%) of 
TCGA cutaneous melanoma samples, whereas somewhat higher rates of 15-
20% of rare acral or mucosal melanomas were found to have KIT mutations 
(112-114). Although KIT represents a verified melanoma oncogene in a relatively 
low percentage of melanomas, the large fraction of sun-exposed cutaneous 
33 
 
melanomas frequently lose KIT expression (120-122), suggesting that KIT may 
play a suppressive role during melanoma formation. 
 
To investigate the role of KIT in melanoma, we tested whether the 
absence of Kit affects melanoma formation by introducing a kit loss-of-function 
mutation into a zebrafish melanoma model that combines melanocyte lineage-
expressed BRAFV600E with a p53 loss-of-function mutation (135). Loss of kit 
caused a significant acceleration of tumor initiation. In both zebrafish tumors and 
human melanoma cell lines, loss of KIT led to an increase in RAS/MAPK 
pathway signaling. Our mechanistic studies suggest that KIT-mediated activation 
of wild-type RAF proteins can dampen oncogenic signaling from BRAFV600E. 
These data indicate that, in the context of a BRAFV600E mutation, KIT acts as a 
tumor suppressor. 
 
Results 
As described below, we aimed to test whether the loss of KIT would 
impact melanoma initiation by using a zebrafish strain that develops fully-
penetrant melanomas driven by human BRAFV600E (135). To first confirm that 
examining the loss of KIT in a BRAFV600E-mutant background was appropriate, 
we investigated whether reduced KIT expression was associated with oncogenic 
BRAF mutations in human melanoma. Based on normalized transcript amounts 
from tumor samples in The Cancer Genome Atlas (TCGA) (78), BRAFV600E-
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mutant melanomas generally expressed lower levels of KIT than melanomas with 
wild-type BRAF (BRAFWT) (Fig. II.1A). Contributing to this difference were 
tumors, in the BRAFWT group that contained KIT gain-of-function mutations. As a 
further indication of the inverse relationship of KIT expression and BRAFV600E 
mutations, gene set enrichment analysis (GSEA) revealed that a set of genes 
upregulated by BRAFV600E (143) was associated with low KIT expression in 
BRAFV600E-mutant melanomas (Fig. II.1B). These data indicate that oncogenic 
BRAF mutations and activity are correlated with low KIT expression in human 
melanoma.  
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Figure II.1 
 
Figure II.1 – BRAFV600E mutations and gene signature are associated with 
low KIT expression in human melanoma  
(A) KIT mRNA expression was analyzed in TCGA melanoma samples that were 
sorted according to BRAF and KIT mutation status, *P value < 0.05; Student’s t 
test. (B) GSEA showing association of a BRAFV600E-induced gene set (143) with 
low KIT expression in TCGA melanoma samples. Nominal P value calculated as 
described (144), where the observed enrichment score was compared to a set of 
1000 randomly generated enrichment scores. 
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 We began investigating the relationship between KIT and BRAFV600E in 
zebrafish by crossing a kit(b5) loss-of-function mutant strain (129), referred to 
hereafter as kit(lf), with a Tg(mitfa:BRAFV600E) strain, that expressed BRAFV600E 
in the melanocyte lineage (135). This was important because it was unclear 
whether melanoma could be investigated in a kit-mutant background - 
melanomas in zebrafish predominantly arise from dorsal regions containing 
scale-associated melanocytes, and kit(lf) zebrafish lack these melanocytes. In 
the resulting kit(lf); Tg(mitfa:BRAFV600E) strain, dorsal scale-associated 
melanocytes were present in a typical net-like pattern, although at a density 
somewhat lower than in Tg(mitfa:BRAFV600E) animals (Fig. II.2A). To determine 
whether BRAFV600E rescued development of dorsal, scale-associated 
melanocytes that were missing in kit(lf) fish or whether the oncogene had merely 
induced mis-migration of otherwise extant stripe-associated melanocytes, we 
further crossed these strains into an ednrb(lf) background (129). Whereas, kit(lf); 
ednrb(lf) double mutants lacked melanocytes entirely, kit(lf); ednrb(lf); 
Tg(mitfa:BRAFV600E) fish still developed a population of dorsal scale-associated 
melanocytes (Fig. II.2B). These results indicate that BRAF can act downstream 
of, or in parallel to, kit to promote melanocyte development, which is consistent 
with KIT receptor signaling through BRAF that is thought to occur in this cell type 
(68,145). 
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Figure II.2 
 
Figure II.2 – BRAFV600E rescues dorsal scale-associated melanocytes 
absent in kit(lf) zebrafish  
(A) Profile images of Tg(mitfa:BRAFV600E), kit(lf), and kit(lf); Tg(mitfa:BRAFV600E) 
adult zebrafish showing rescue of dorsal, scale-associated melanocytes in kit(lf); 
Tg(mitfa:BRAFV600E) zebrafish. (B) Profile and dorsal images of kit(lf); ednrb(lf), 
and kit(lf); ednrb(lf); Tg(mitfa:BRAFV600E) adult zebrafish showing melanocyte 
rescue in kit(lf); ednrb(lf); Tg(mitfa:BRAFV600E) zebrafish. The mean density of 
melanocytes per square millimeter ±SEM on dorsal scales is listed for each 
genotype. 
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Rescue of melanocyte development by BRAFV600E enabled us to test 
whether the loss of kit would have an effect on BRAFV600E-driven melanoma 
formation. Before doing so, we assessed whether kit was expressed in 
melanomas from Tg(mitfa:BRAFV600E); p53(lf) fish. In contrast to most human 
BRAFV600E-mutant melanomas, kit was expressed in Tg(mitfa:BRAFV600E); p53(lf) 
zebrafish melanomas (Fig. II.3A), making this model useful for interrogating the 
effects of the loss of kit in melanoma formation. We established a kit(lf); 
Tg(mitfa:BRAFV600E); p53(lf) strain and monitored tumor onset in these animals 
as compared to Tg(mitfa:BRAFV600E); p53(lf) controls. The kit(lf); 
Tg(mitfa:BRAFV600E); p53(lf) fish had markedly accelerated melanoma onset 
relative to Tg(mitfa:BRAFV600E); p53(lf) animals; the median melanoma onset in 
kit(lf); Tg(mitfa:BRAFV600E); p53(lf) fish was 21 weeks, whereas it was 35 weeks 
in a Tg(mitfa:BRAFV600E); p53(lf) background (Fig. II.3B). To confirm that 
accelerated onset was due to the loss of kit rather than background effects, we 
asked whether a second, independently-derived kit loss-of-function allele, 
kit(e78) (146), could also affect onset. Indeed, the kit(e78);Tg(mitfa:BRAFV600E); 
p53(lf) strain experienced accelerated tumor onset similar to kit(b5); 
Tg(mitfa:BRAFV600E); p53(lf) fish (Fig. II.4A), indicating that the loss of kit is 
responsible for the accelerated tumor onset. Melanomas from kit(lf); 
Tg(mitfa:BRAFV600E); p53(lf) (all further use of “kit(lf)” refers to the kit(b5) strain) 
were more frequently invasive, with 65% of tumors having penetrated through the 
musculature and into the spinal column at four weeks post onset, while only 9% 
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of tumors from control fish displayed such invasion (Fig. II.3C and Table II.1). To 
investigate whether tumor invasiveness was a cell-intrinsic property, donor 
blastomeres from kit(lf); Tg(mitfa:BRAFV600E); p53(lf) embryos were transplanted 
into Tg(mitfa:BRAFV600E); p53(lf); mitfa(lf) blastula-stage host embryos or, 
conversely, donor blastomeres from Tg(mitfa:BRAFV600E); p53(lf) embryos were 
transplanted into kit(lf); Tg(mitfa:BRAFV600E); p53(lf); mitfa(lf) blastula-stage host 
embryos. Invasiveness was determined to be a cell-autonomous property as 
melanomas derived from kit(lf); Tg(mitfa:BRAFV600E); p53(lf) cells were invasive 
in a Tg(mitfa:BRAFV600E); p53(lf); mitfa(lf) background, whereas melanomas 
derived from Tg(mitfa:BRAFV600E); p53(lf) cells in a kit(lf); Tg(mitfa:BRAFV600E); 
p53(lf); mitfa(lf) background were not invasive (Fig. II.4B and II.4C). These 
results indicate that the loss of kit promotes tumor onset and invasiveness, 
demonstrating that kit acts as a tumor suppressor in BRAFV600E-mutant 
melanomas. 
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Figure II.3 
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Figure II.3 – kit suppresses BRAFV600E-driven melanoma formation 
(A) In-situ hybridization of a representative Tg(mitfa:BRAFV600E); p53(lf) zebrafish 
melanoma with kit antisense and sense probes. Dashed yellow lines indicate the 
border between normal muscle tissue and tumor. Yellow squares indicate the 
locations of the inset magnified for the antisense images in the center. Scale bars 
= 150 µm (B) Tumor onset curves for Tg(mitfa:BRAFV600E); p53(lf) and kit(lf); 
Tg(mitfa:BRAFV600E); p53(lf) fish. P value = 8.46 x 10-12; log-rank test. (C) 
Representative adult zebrafish with dorsal melanomas. Lower panels show 
transverse sections from non-invasive Tg(mitfa:BRAFV600E); p53(lf) and invasive 
kit(lf); Tg(mitfa:BRAFV600E); p53(lf) tumors. Quantification of invasiveness is 
shown in Table 1. Scale bars = 0.5 mm. 
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Figure II.4 
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Figure II.4 – kit loss-of-function alleles accelerate melanoma onset and 
increase invasiveness 
(A) Tumor onset curves showing melanoma-free survival for 
Tg(mitfa:BRAFV600E); p53(lf), kit(b5); Tg(mitfa:BRAFV600E); p53(lf), and kit(e78); 
Tg(mitfa:BRAFV600E); p53(lf) zebrafish. kit(b5) is the allele referred to as kit(lf) 
elsewhere in the manuscript. P value = 8.46 x 10-12 for kit(b5); 
Tg(mitfa:BRAFV600E); p53(lf) vs. Tg(mitfa:BRAFV600E); p53(lf), P value = 8.75 x 10-
10 for kit(e78); Tg(mitfa:BRAFV600E); p53(lf) vs. Tg(mitfa:BRAFV600E); p53(lf), and 
P value = 0.287 for kit(b5); Tg(mitfa:BRAFV600E); p53(lf) vs. kit(e78); 
Tg(mitfa:BRAFV600E); p53(lf); log-rank test. (B) Hematoxylin and eosin staining of 
a transverse section from a Tg(mitfa:BRAFV600E); p53(lf); mitfa(lf) host with a 
melanoma derived from kit(lf); Tg(mitfa:BRAFV600E); p53(lf) donor cells. 3/3 such 
animals had melanomas that invaded into the musculature. (C) Transverse 
zebrafish section from a kit(lf); Tg(mitfa:BRAFV600E); p53(lf); mitfa(lf) host with a 
melanoma derived from Tg(mitfa:BRAFV600E); p53(lf) donor cells. 0/4 animals had 
melanomas that invaded into the musculature. Scale bar = 0.5 mm.  
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Table II.1 
 
  
 
 
Table II.1 – Melanoma invasiveness in kit(lf) mutant zebrafish 
Percentages of fish that were positive for melanoma cells at the indicated 
anatomical depth relating to the representative images in Fig. II.3C. 
Tg(mitfa:BRAFV600E); p53(lf) versus kit(lf); Tg(mitfa:BRAFV600E); p53(lf), P value = 
0.0004; chi-squared test. 
  
 Tg(mitfa:BRAFV600E); 
p53(lf) (n=11) 
kit(lf); Tg(mitfa:BRAFV600E); 
p53(lf) (n=17) 
Skin 100% 100% 
Muscle 36% 100% 
Muscle + 
spinal column 9% 65% 
45 
 
 To explore whether signaling downstream from kit is altered in kit(lf); 
Tg(mitfa:BRAFV600E); p53(lf) tumors, we analyzed levels of phosphorylated Erk 
(pErk), phosphorylated Akt (pAkt), and Mitfa by western blotting. There was no 
significant difference in Akt activation or Mitfa expression between kit(lf); 
Tg(mitfa:BRAFV600E); p53(lf) and Tg(mitfa:BRAFV600E); p53(lf) tumors (Fig. II.5A-
C). However, kit(lf); Tg(mitfa:BRAFV600E); p53(lf) tumors did possess 2.6-fold 
higher levels of pErk (Fig. II.6A and II.6B). Phospho-specific MEK (pMEK) 
antibodies did not cross react with zebrafish MEK protein, so we could not 
quantify pMEK/MEK ratios to further measure pathway activity. ERK activation is 
the major conduit for BRAFV600E signaling, therefore KIT inhibition of melanoma 
formation could be mediated by inhibition of oncogenic BRAFV600E signaling. 
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Figure II.5 
 
  
47 
 
Figure II.5 – Mitfa levels and Akt activation are not significantly altered in 
kit(lf); Tg(mitfa:BRAFV600E); p53(lf) zebrafish melanomas  
(A) Western blots for Mitfa, pAkt (S473), Akt, and α-Tubulin in seven 
Tg(mitfa:BRAFV600E); p53(lf) and ten kit(lf); Tg(mitfa:BRAFV600E); p53(lf) zebrafish 
melanoma lysates. (B) Quantification of Mitfa/α-Tubulin. (C) Quantification of 
pAkt/Akt. Mitfa/α-Tubulin and pAkt/Akt signals were normalized to the mean 
Mitfa/α-Tubulin and pAkt/Akt signals, respectively, from Tg(mitfa:BRAFV600E); 
p53(lf) tumor samples. Box plot edges represent minimum, 1st quartile, median, 
3rd quartile, and maximum of normalized values. P values of 0.605 and 0.958 for 
(B) and (C), respectively. NS, not significant; Students t test. 
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Figure II.6 
 
Figure II.6 – kit suppresses BRAFV600E oncogenic signaling in zebrafish 
melanomas 
(A) Western blots and (B) quantification of pErk/Erk for Tg(mitfa:BRAFV600E); 
p53(lf) and kit(lf); Tg(mitfa:BRAFV600E); p53(lf) zebrafish melanomas. pERK/ERK 
signals were normalized to the mean pERK/ERK signal from 
Tg(mitfa:BRAFV600E); p53(lf) tumor samples. Box plot edges represent minimum, 
1st quartile, median, 3rd quartile, and maximum normalized values. P value < 
0.05; Student’s t test.   
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 To determine whether KIT also suppressed RAS/MAPK pathway signaling 
in human melanoma cells, we knocked down KIT in 888MEL cells, a rare 
melanoma cell line that has a BRAFV600E mutation but still expresses KIT (124). 
888MEL cells might sustain KIT expression through the transcription factor AP-2, 
which directly binds and upregulates the KIT promoter (147). Although AP-2 
expression is frequently absent in melanoma cell lines, it has been previously 
shown that 888MEL cells have high levels of this factor (147,148). We observed 
BRAFV600E activity by measuring pMEK. MEK is phosphorylated by BRAF and is 
the most direct measure of pathway activity downstream of BRAF activation. In 
cells where KIT was knocked down with either of two independent shRNAs, 
levels of pMEK increased (Fig II.7A). Also, KIT-knockdown cells more readily 
formed colonies when plated at low density in an anchorage-dependent colony 
formation assay (Fig. II.7B). Furthermore, stimulation of KIT-expressing 888MEL 
cells with Stem Cell Factor (SCF), the KIT ligand, reduced both MEK activation 
and growth of these cells without affecting expression of either KIT or BRAFV600E 
(Fig. II.7C and II.7D). These experiments demonstrate that KIT can function in 
888MEL cells to suppress RAS/MAPK pathway activity and reduce their growth 
potential. 
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Figure II.7 
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Figure II.7 – KIT suppresses BRAFV600E oncogenic signaling in a human 
melanoma cell line 
(A) Western blots of pMEK and MEK for human melanoma 888MEL cells 
expressing a control non-silencing shRNA or either of two KIT-targeting shRNAs. 
(B) Colony formation assay for 888MEL cells expressing a control non-silencing 
shRNA or either of two KIT-targeting shRNAs. (C) Western blot and 
quantification of 888MEL cells treated with 200 ng/ml Bovine Serum Albumin 
(BSA) or Stem Cell Factor (SCF) 30 minutes prior to protein harvest. (D) 888MEL 
cells were counted during adherent growth with 200 ng/ml BSA or SCF treatment 
administered on days 1 and 4. Data in B, C, and D are represented as mean 
±SEM for experiments done in biological triplicate. *P value < 0.05, **P value < 
0.01, NS, not significant; Student’s t test. 
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We considered different possibilities for how KIT could inhibit BRAFV600E-
driven signaling. Since KIT activity normally promotes downstream MEK/ERK 
signaling, it is paradoxical that the loss of KIT would lead to an increase in 
downstream pathway activity. Excess ERK activation invokes negative feedback 
loops, so perhaps KIT upregulates signaling to a level where negative feedback 
is needed to dampen pathway activity. We consider such mechanisms unlikely 
because A) a major mode of negative feedback is through upregulation of dual-
specificity phosphatases, which remove activating phosphoryl groups from ERK 
(149) – upon loss of KIT in 888MEL cells, we found increased pMEK (Fig. II.7A), 
arguing that the effect of KIT loss is not centered on ERK, but instead occurs 
more upstream in the pathway, and B) negative feedback is also accomplished 
by inhibitory phosphorylation on BRAF by ERK – BRAFV600E is insensitive to such 
inhibition and thus not subject to this type of negative feedback (89).  
 
For these reasons, we considered mechanisms whereby KIT could more 
directly interfere with BRAFV600E-driven signaling. RTK activation of RAS leads to 
membrane-localized BRAF:CRAF dimer formation and activation (84,150). The 
V600E mutation shifts BRAF into a constitutively active conformation capable of 
phosphorylating MEK in a RAS-independent manner with vastly increased kinase 
activity (90,151,152). Previously it was reported that BRAFV600E kinase activity 
was reduced when it heterodimerized with CRAF (153), so we hypothesized that 
KIT could drive formation of BRAFV600E:CRAF complexes, which would have less 
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activity than uncomplexed BRAFV600E. To test this, we used a bioluminescence 
resonance energy transfer (BRET) assay to measure the interaction between 
Renilla Luciferase-tagged CRAF (RLuc-CRAF) and Venus-tagged BRAFV600E (V-
BRAFV600E). We determined transfection conditions in HEK293T cells where 
formation of V-BRAFV600E:RLuc-CRAF dimers was induced by co-expression with 
NRASQ61K as a constitutively active surrogate for pathway stimulation (STIM). 
Under stimulating conditions, an increase in dimerization was measured between 
V-BRAFV600E and RLuc-CRAF as a decrease in BRET50, the acceptor/donor ratio 
that yields 50 percent of maximal signal of a BRET titration curve (Fig. II.8A and 
Table II.2). We used site directed mutagenesis of the V-BRAFV600E construct to 
introduce an R188L mutation, which disrupts the RAS-binding domain of BRAF 
(82). V-BRAFR188L/V600E was less sensitive to upstream stimulation-induced RLuc-
CRAF binding, as indicated by a less dramatic shift in the BRET50 for its titration 
curve (Fig. II.8A and Table II.2). Levels of pMEK increased when cells 
expressing V-BRAFV600E were stimulated by upstream pathway activity, but did 
not increase as much for V-BRAFR188L/V600E stimulation (Fig. II.8A and II.8C). 
These data suggest that, in the context of upstream stimulation, formation of 
BRAFV600E:CRAF complexes does not diminish the total signaling output of 
BRAFV600E-mutant cells. 
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Figure II.8 
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Figure II.8 – Upstream stimulation drives BRAFV600E:CRAF dimer formation 
and increases oncogenic signaling  
(A) BRET titration curves measuring interaction between V-BRAFV600E and RLuc-
CRAF in the presence or absence of stimulation with NRASQ61K (STIM). The 
induction of a VBRAFV600E:RLuc-CRAF interaction signal was modestly 
diminished when the RAS binding domain of V-BRAFV600E was disrupted with an 
R188L mutation. Data points denote the mean ±SEM for either the 
[Acceptor]/[Donor] ratio on the x-axis, or the BRET signal on the y-axis for three 
biological replicates. Quantification of BRET50 values is shown in Supplementary 
Table II.2. (B) Western blots of pMEK and MEK from HEK293T cells expressing 
V-BRAFV600E with or without upstream stimulation. The BRAFV600E band in lane 4 
runs slightly higher when activated by upstream stimulation. (C) Western blots of 
pMEK and MEK from HEK293T cells expressing V-BRAFR188L/V600E with or 
without upstream stimulation. 
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Table II.2 
 
 
 
 
Table II.2 – BRET50 values for V-BRAFV600E and V-BRAFR188L/V600E 
BRET50 and BRET50 fold changes for Venus-BRAFV600E or Venus-BRAFR188L/V600E 
and RLuc-CRAF in HEK293T cells in the presence or absence of stimulation with 
NRASQ61K (STIM). Associated with the BRET titration curve in Supplementary 
Fig. II.8A. Data obtained from biological triplicate samples. **P value < 0.01, ***P 
value < 0.001, ****P value < 0.0001, NS, not significant; F-test. 
 
  
 V-BRAFV600E 
BRET50 
V-BRAFR188L/V600E 
BRET50 
Fold  
difference 
+ STIM 1.293 1.525 1.179*** 
+ EMPTY 3.251 2.964 0.912 (NS) 
Fold change 2.514**** 1.944**  
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We therefore examined another hypothesis. Since the BRAFWT allele can 
continue to be expressed in BRAFV600E-mutant cancer cells (15,154,155), we 
reasoned that upstream activation of this pathway could recruit BRAFWT proteins 
to form dimers, thus engaging pathway components which possess relatively low 
kinase activity (Fig. II.15). To determine if BRAFWT:CRAF dimers could dampen 
BRAFV600E activity, we again used BRET assays to determine transfection 
conditions in HEK293T cells that yielded stimulation-dependent increases in V-
BRAFWT:RLuc-CRAF heterodimers. Upstream stimulation induced a decrease in 
BRET50, indicating a robust interaction of V-BRAFWT and RLuc-CRAF (Fig. II.9A 
and Table II.3). Upstream stimulation only modestly induced an interaction 
between a V-BRAFR188L mutant and RLuc-CRAF. Using transfection conditions 
that yielded low, medium, and near saturating levels of V-BRAFWT:RLuc-CRAF 
interaction, we measured MEK phosphorylation. With upstream stimulation, 
pMEK levels increased when any amount of BRAFWT was expressed in cells (Fig. 
II.9B). A less robust increase was observed when BRAFR188L was expressed. We 
next asked whether expression of BRAFWT could impact BRAFV600E-driven MEK 
activation. In the absence of pathway stimulation, neither the addition of BRAFWT 
nor BRAFR188L affected pMEK levels in BRAFV600E-expressing cells (Fig. II.9C). 
However, with upstream stimulation, BRAFWT expression reduced pMEK levels in 
BRAFV600E-expressing cells, whereas BRAFR188L expression had no effect (Fig. 
II.9D). Quantification of relative pMEK/MEK was calculated in biological triplicate 
samples of all BRAF titrations for each experimental condition (Fig. II.9E-F). 
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Figure II.9 
 
  
59 
 
Figure II.9 – Upstream stimulation of BRAFWT can dampen BRAFV600E 
oncogenic signaling 
(A) BRET titration curves measuring association between RLuc-CRAF and 
varying levels of V-BRAFWT or V-BRAFR188L in the presence or absence of 
stimulation from NRASQ61K (STIM). Data points represent the mean ±SEM for 
either the [Acceptor]/[Donor] ratio on the x-axis, or the BRET signal on the y-axis 
for three biological replicates. Quantification of BRET50 values is shown in Table 
2. (B-D) Western blots of pMEK and MEK from HEK293T cells expressing 
BRAFWT or BRAFR188L with upstream stimulation alone (B), with BRAFV600E alone 
(C), or with both stimulation and BRAFV600E (D). The highest bands on the BRAF 
blots are Venus-tagged BRAFV600E, whereas the lower bands are untagged 
BRAFWT or BRAFR188L, with BRAFWT running slightly higher in lane 2 of panels B 
and D when activated by upstream stimulation. (E-G) Quantification of 
pMEK/MEK levels for cells expressing varying levels of BRAFWT or BRAFR188L 
with upstream stimulation alone (E), with BRAFV600E alone (F), or with both 
stimulation and BRAFV600E (G). Fold changes were calculated in comparison to 
control cells in which EGFP was expressed instead of BRAFV600E or BRAFR188L. 
Quantification indicates the mean ±SEM of three biological replicate experiments. 
P values were calculated comparing each condition of BRAFWT to BRAFR188L 
expression. *P value < 0.05, **P value < 0.01, ***P value < 0.001, ****P value < 
0.0001; Student’s t test. 
  
60 
 
Table II.3 
 
 
 
 
Table II.3 – BRET50 values for V-BRAFWT and V-BRAFR188L 
BRET50 and BRET50 fold changes for each of two Venus-BRAF constructs 
expressed with RLuc-CRAF in HEK293T cells in the presence or absence of 
stimulation with NRASQ61K (STIM). Associated with the BRET titration curve in 
Fig. 4A. Data obtained from biological triplicate samples. ***P value < 0.001, 
****P value < 0.0001, NS, not significant; F-test. 
 
 
  
 
V-BRAFWT 
BRET50 
V-BRAFR188L 
BRET50 
Fold 
difference 
+ STIM 1.037 4.050 3.905**** 
+ EMPTY 4.473 4.711 1.053 (NS) 
Fold change 4.313**** 1.163***  
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We repeated these tests using HEK293T cells stably expressing KIT or 
enhanced green fluorescent protein (EGFP). Upon stimulation with SCF, we 
detected KIT phosphorylation (Fig. II.10A). In addition, SCF treatment increased 
levels of pMEK and promoted the interaction of V-BRAFWT with RLuc-CRAF (Fig. 
II.10A and II.10B and Table II.4), although both were more modest than the 
increases observed when cells were stimulated by NRASQ61K. SCF stimulated, 
KIT or EGFP-expressing cells were transfected with BRAF constructs and, as 
before, BRAFWT reduced BRAFV600E-driven signaling, but only in the KIT 
expressing cells (Fig. II.10C and II.10D). These data indicate that BRAFWT can 
attenuate BRAFV600E-driven MEK activation, and this attenuation is most 
pronounced in the context of robust upstream stimulation. 
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Figure II.10 
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Figure II.10 – Effects of KIT overexpression on RAF dimer formation and 
downstream signaling in HEK293T cells  
(A) Western blots of lysates from HEK293T cells transduced with lentiviral 
constructs to express either KIT or EGFP. Cells harvested at indicated time 
points after addition of 200 ng/ml SCF. (B) BRET titration curves measuring 
association between V-BRAFWT and RLuc-CRAF in HEK293T cells expressing 
KIT, where 400 ng/ml of either BSA or SCF was administered 20 minutes prior to 
signal assessment. Quantification of BRET50 values is shown in Supplementary 
Table II.4. (C) Western blots and quantification of pMEK/MEK from HEK-KIT cells 
expressing BRAFV600E + EGFP or BRAFV600E + BRAFWT and HEK-GFP cells 
expressing BRAFV600E + EGFP or BRAFV600E + BRAFWT. Samples harvested 30 
minutes after addition of 400 ng/ml SCF. Bar graphs represent the mean ±SEM 
for biological triplicate samples. *P value < 0.05; Student’s t test. 
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Table II.4  
 
 
 
 
Table II.4 – BRET50 values for V-BRAFWT driven by KIT and SCF 
BRET50 and BRET50 fold changes for Venus-BRAFWT with RLuc-CRAF in 
HEK293T cells expressing KIT and stimulated with SCF. Associated with the 
BRET titration curve in Fig. II.10B. Data obtained from biological triplicate 
samples. *P value < 0.05; F-test. 
  
 
V-BRAFWT 
BRET50 
+ SCF 5.737 
+ BSA 7.516 
Fold change 1.310* 
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 Our studies in HEK293T cell lines suggested that signaling through 
BRAFWT was important for KIT-mediated tumor suppression. To further explore 
the relationship between KIT and BRAFWT, we examined signaling in melanoma 
cells. A375 cells are BRAFV600E-mutant and have no detectable BRAFWT 
expression, whereas UACC257 cells are BRAFV600E-mutant but retain expression 
of BRAFWT (156). Neither cell line expressed KIT endogenously (Fig. II.11A). To 
reconstitute upstream signaling in these cells, we introduced exogenous KIT and 
grew cells in the presence of SCF. KIT expression promoted growth of A375 cells 
and increased pMEK levels. The opposite was observed in UACC257 cells, in 
which KIT expression slowed growth and decreased pMEK levels (Fig. II.11B-D). 
These results further suggest that the tumor suppressive activity of KIT is related 
to the expression of BRAFWT. Additionally, it is notable that 888MEL cells, which 
displayed KIT-mediated growth and signaling inhibition, also expressed BRAFWT 
(Fig. II.11E and II.11F). Lastly, we examined whether the link between KIT and 
BRAFWT extended to melanoma clinical data. TCGA melanoma samples were 
segregated into quintiles based on BRAFWT-to-BRAFV600E ratios, and the upper-
most (high BRAFWT:BRAFV600E) and lower-most (low BRAFWT:BRAFV600E) 
quintiles were examined. Within each group, cohorts with high and low KIT 
expression were defined. In the high BRAFWT:BRAFV600E group, patients whose 
tumors expressed high levels of KIT experienced a survival benefit as compared 
to patients whose tumors had low KIT expression (Fig. II.12A). In the low 
BRAFWT:BRAFV600E group, there was no correlation between KIT expression and 
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patient survival (Fig. II.12B). We further observed that high KIT expression was 
associated with a decreased likelihood for melanomas to present with regional or 
distant metastases (tumor stage III/IV) amongst the group of patients with high 
BRAFWT:BRAFV600E ratios (Table II.5). KIT expression had no association with the 
likelihood of metastases in the group of patients with low BRAFWT:BRAFV600E 
ratios (Table II.5). We further analyzed potential relationships between KIT 
expression and other common melanoma tumor suppressors. This analysis 
revealed no significant link between KIT and the loss of PTEN, TP53, or 
CDKN2A, suggesting that there is no interdependence or redundancy of KIT with 
these suppressors (Table II.6).  
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Figure II.11 
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Figure II.11 – Synergistic effect of KIT and BRAFWT expression on 
melanoma cell growth  
(A) Western blots of KIT overexpression in A375 and UACC257 cells. (B and C) 
Adherent growth of A375 (B) or UACC257 (C) human melanoma cell lines 
expressing either EGFP or KIT. Cells were grown in DMEM with 0.5% FBS plus 
200 ng/ml SCF added at days 1 and 4. (D). Western blots and quantification of 
lysate from A375 and UACC257 cells expressing EGFP or KIT. Cells were grown 
and treated with SCF as above. Data represent the mean ±SEM for samples 
done in biological triplicate. *P value < 0.05, **P value < 0.01, ***P value < 0.001; 
Student’s t test. (E and F) Electropherograms from Sanger sequencing of a 
BRAF PCR product from 888MEL (E) or A375 (F) cDNA. Positions of peaks 
corresponding to BRAFV600E and BRAFWT alleles are indicated. 
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Figure II.12 
 
Figure II.12 – Synergistic effect of KIT and BRAFWT expression on 
melanoma clinical outcome  
Overall survival of human melanoma patients over time for high and low KIT 
expression cohorts from (A) the high BRAFWT:BRAFV600E group, P value = 
0.0024; log-rank test, and (B) the low BRAFWT:BRAFV600E group, P value = 
0.8927; log-rank test. 
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Table II.5 
 
Table II.5 – Association of KIT expression with clinical parameters of 
melanoma progression 
TCGA clinical parameters of patients with melanomas in high or low 
BRAFWT:BRAFV600E groups and further subdivided into high and low KIT 
expression cohorts. P values were calculated for Breslow depth and mitotic rate 
by Student’s t tests and for ulceration and regional/distant metastasis by Fisher’s 
exact tests. 
  
 
High BRAF
WT
:BRAF
V600E 
Tumors Low BRAF
WT
:BRAF
V600E 
Tumors 
 Low KIT High KIT 
Fold 
change 
P value Low KIT High KIT 
Fold 
change 
P value 
Breslow depth ± SEM 
(mm) 
3.1 ± 0.9 
(n=7) 
1.4 ± 0.3 
(n=9) 
0.47 0.08 
1.5 ± 0.3 
(n=8) 
3.1 ± 0.9 
(n=8) 
2.09 0.16 
Ulceration 
4/6 
(66.7%) 
1/7 
(14.3%) 
0.21 0.10 
2/3 
(33.3%) 
5/7 
(28.6%) 
0.86 0.99 
Mitotic rate ± SEM  
(per mm
2
) 
8.0 ± 3.0 
(n=5) 
3.1 ± 1.0 
(n=8) 
0.39 0.09 
6.0 ± 2.3 
(n=3) 
13.0 ± 
6.6 
(n=3) 
2.30 0.42 
Regional/Distant 
Metastasis (Stage 
III/IV) 
8/10 
(80.0%) 
2/9 
(22.2%) 
0.28 0.02 
5/11 
(45.5%) 
5/11 
(45.5%) 
1.00 0.99 
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Table II.6 
PTEN 
alterations 
Mutation 
Copy number 
loss 
Low mRNA 
expression 
High 
methylation 
Low protein 
expression 
High KIT 0.9999 0.9999 0.2292 0.6275 0.0856 
Low KIT 0.7583 0.6275 0.6275 0.1422 0.3795 
 
TP53 
alterations 
Mutation 
Copy number 
loss 
Low mRNA 
expression 
High 
methylation 
Low protein 
expression 
High KIT 0.1087 0.9999 0.6275 0.8098 0.2593 
Low KIT 0.5135 0.9999 0.4703 0.9999 0.5716 
 
CDKN2A 
alterations 
Mutation 
Copy number 
loss 
Low mRNA 
expression 
High 
methylation 
Low protein 
expression 
High KIT 0.3823 0.9999 0.8098 0.9999 0.5716 
Low KIT 0.3823 0.4703 0.4703 0.9999 0.7703 
 
Table II.6 – Lack of association of KIT expression with PTEN, TP53, and 
CDKN2A alterations in human melanoma 
This analysis compared how frequently PTEN, TP53, or CDKN2A tumor 
suppressor genes (TSGs) were altered in patients with melanomas having high 
or low KIT mRNA expression. We compared the upper-most 25% of KIT-
expressing samples to the remaining 75% of samples to measure enrichment of 
TSG alterations in melanomas with high KIT expression. Additionally, we 
compared the lower 25% of KIT-expressing samples to the upper 75% of 
samples to measure enrichment of TSG alterations in melanomas with low KIT 
expression. We classified a sample as having a TSG alteration if it contained a 
mutation or whether the sample was in the lowest (for copy number, mRNA 
expression, and protein expression) or highest (DNA methylation) quartile within 
each respective category. For each category, we compared the high or low KIT-
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expressing groups for enrichment of the TSG alterations using Fisher’s exact 
tests. These three tables report the P values of these comparisons for each 
category with each TSG. 
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To test the link between KIT and BRAFWT in vivo, we employed the 
established ‘miniCoopR’ method for generating transgenic melanomas in 
zebrafish (136). The miniCoopR vector juxtaposes a transgene of interest to a 
copy of the mitfa melanocyte specification gene. When this construct is injected 
into melanocyte-deficient mitfa(lf) zebrafish embryos, melanocytes are rescued 
cell-autonomously by the mitfa gene, and each rescued melanocyte expresses 
the neighboring transgene of interest (Fig. II.13A). miniCoopR vectors containing 
either BRAFWT or EGFP open reading frames under control of the mitfa promoter 
were injected into Tg(mitfa:BRAFV600E); p53(lf); mitfa(lf) embryos, and animals 
with rescued melanocytes were monitored weekly for melanoma onset. 
Expression of BRAFWT delayed median tumor onset by seven weeks as 
compared to expression of EGFP (Fig. II.13B). This change was not due to 
altered expression of BRAFV600E, as levels of this oncoprotein were similar in 
BRAFWT and EGFP-expressing cohorts (Fig. II.14). To determine if this delayed 
onset was dependent on kit, the same experiment was performed, except 
miniCoopR constructs were injected into a kit(lf); Tg(mitfa:BRAFV600E); p53(lf); 
mitfa(lf) background. In this background, melanocyte rescue was poor and 
consequently tumor onset of the miniCoopR-EGFP control cohort was slower as 
compared to miniCoopR-EGFP in a Tg(mitfa:BRAFV600E); p53(lf); mitfa(lf) 
background. Within the kit(lf); Tg(mitfa:BRAFV600E); p53(lf); mitfa(lf) background, 
the miniCoopR-EGFP control cohort and miniCoopR-BRAFWT animals exhibited 
no difference in melanoma onset (Fig. II.13C). These data indicate that BRAFWT 
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can inhibit BRAFV600E-driven tumor onset, but this inhibition is dependent upon 
expression of KIT. 
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Figure II.13 
 
Figure II.13 – BRAFWT delays BRAFV600E-driven melanoma formation in a kit-
dependent manner 
(A) Overview of a miniCoopR tumor onset experiment as described in Materials 
and Methods. Tumor onset was monitored weekly for fish expressing BRAFWT or 
EGFP. (B) Tumor onset of Tg(mitfa:BRAFV600E); p53(lf); mitfa(lf) zebrafish with 
melanocytes rescued by miniCoopR-BRAFWT or miniCoopR-EGFP, P = 8.05 x 
10-7 ; log-rank test. (C) Tumor onset of kit(lf); Tg(mitfa:BRAFV600E); p53(lf); 
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mitfa(lf) zebrafish with melanocytes rescued by miniCoopR-BRAFWT or 
miniCoopR-EGFP, P value = 0.664; log-rank test.   
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Figure II.14 
 
Figure II.14 – BRAFWT overexpression does not affect BRAFV600E levels in 
zebrafish melanomas  
Western blots and quantification of lysate taken from Tg(mitfa:BRAFV600E); 
p53(lf); mitfa(lf) zebrafish tumors generated with miniCoopR-EGFP or 
miniCoopR-BRAFWT expression constructs. Data represent the mean of either 
BRAFV600E/α-Tubulin or total BRAF/α-Tubulin ±SEM normalized to the mean of 
the miniCoopR-EGFP group for BRAFV600E/α-Tubulin or total BRAF/α-Tubulin, 
respectively. The columns represent three miniCoopR-EGFP and eleven 
miniCoopR-BRAFWT tumors. *P value < 0.05; Student’s t test. 
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Discussion 
Our results show that KIT can suppress BRAFV600E-driven melanoma 
formation. The loss of KIT resulted in increased BRAFV600E-driven oncogenic 
signaling in a zebrafish melanoma model and human melanoma cells. Our 
mechanistic studies suggest that BRAFV600E activity can be reduced by BRAFWT, 
but only under conditions where BRAFWT receives upstream pathway stimulation. 
In vivo data support this notion, as expression of BRAFWT suppressed 
BRAFV600E-driven melanoma initiation in a KIT-dependent manner. 
 
 There are several possible ways in which KIT could inhibit BRAFV600E-
driven oncogenic signaling. Important negative regulators of oncogenic signaling 
include the dual-specificity phosphatases (DUSPs), which dephosphorylate and 
inactivate ERK (149,157). Potentially, KIT could stimulate DUSP activity either by 
signaling through ERK or by signaling independently, leading to pathway 
inhibition. However, upon knockdown of KIT in BRAFV600E-mutant melanoma 
cells, we observed increased pMEK levels. As negative feedback from DUSPs is 
not expected to have an effect on MEK phosphorylation status (88,149), this led 
us to further investigate potential mechanisms upstream of ERK. We also 
considered a mechanism whereby KIT signaling would drive dimerization of 
BRAFV600E with CRAF, which has been reported to lower the kinase activity of 
BRAFV600E (153). While this is an attractive model, additional observations 
suggest that the situation is more complex. In our assay, we did not find 
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reduction of downstream signaling when BRAFV600E was driven into dimers with 
CRAF. Our assay differs from the one used by Karreth et al. in that we measured 
downstream signaling (i.e. MEK phosphorylation) under conditions of upstream 
pathway stimulation. Stimulation not only facilitates membrane recruitment and 
dimerization of RAF species, but also promotes their activation through 
phosphorylation at a series of sites in the negatively-charged region (152). It is 
possible that BRAFV600E:CRAF dimers, under conditions of upstream stimulation, 
receive additional activating cues, enhancing the activity of these species. 
 
An alternative model to explain our findings would have the ratio of high 
activity to low activity BRAF species determine flux through the signaling 
pathway (Fig. II.15). In this model, under conditions of no upstream stimulation, 
only high activity BRAFV600E would be functional. By contrast, upon upstream 
stimulation a mixture of low activity BRAFWT:CRAF and high activity 
BRAFV600E:CRAF dimers form. Although upstream stimulation could increase the 
collective number of active BRAF species, overall pathway signaling would be 
diminished if low activity BRAFWT:CRAF species have a prominent role in 
determining signaling flux. Such a role could manifest in a variety of ways. For 
example, BRAFWT:CRAF dimers could compete with BRAFV600E:CRAF dimers for 
interaction with their shared MEK substrate. Although not considered in our 
analysis, BRAFWT and BRAFV600E could also potentially compete for interaction 
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with KSR scaffolding proteins (158). In each of these examples, any interaction 
of BRAFWT with limiting downstream components could attenuate signaling.  
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Figure II.15 
 
Figure II.15 – Model of pathway stimulation that could reduce signaling of 
BRAFV600E-mutant cells through activation of BRAFWT 
Under normal signaling conditions, KIT will promote activation of NRAS leading 
to stimulation of active BRAF:CRAF dimers that will phosphorylate MEK with low 
kinase activity leading to normal activation of the MAPK pathway. Introduction of 
a BRAFV600E mutation to these cells would result in indiscriminate activation of 
either high-activity BRAFV600E:CRAF or low-activity BRAFWT:CRAF dimers 
resulting in moderate pathway activity. Lastly, the BRAFWT expressed in a 
BRAFV600E-mutant cell that lacks upstream pathway stimulation due to the loss of 
KIT will remain inactive in the cytoplasm leaving all signaling apparatus to be 
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used by BRAFV600E monomers or homodimers that possess high intrinsic kinase 
activity, resulting in overall high pathway activation. 
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These proposed mechanisms highlight the interplay between wild-type 
and oncogenic signaling in tumors. During tumorigenesis, oncogenic mutations in 
genes typically affect one allele, leaving the other unaffected. In tumors driven by 
oncogenic RAS genes, loss of the corresponding wild-type gene is frequently 
observed (159). A rationale for this loss comes from elegant genetic studies in 
the mouse which showed that the wild-type RAS gene has a tumor suppressive 
effect in certain tumor types (160). By contrast, loss of the BRAFWT allele is rare 
in tumors driven by oncogenic BRAF, and co-expression of wild-type and 
oncogenic variants is evident in the majority of tumors (15). In such tumors we 
propose that signaling through BRAFWT has a suppressive effect, but that the 
loss of KIT effectively abrogates this effect. More generally, our results reveal 
that, under certain circumstances, an unexpected increase of oncogenic 
RAS/MAPK pathway activity could occur upon loss or inhibition of upstream 
signaling components. 
 
Materials and Methods 
Analyses of The Cancer Genome Atlas (TCGA)  
Data from 384 human melanoma RNA-seq samples were downloaded 
from the Cancer Genomics Hub (CGHub) (https://cghub.ucsc.edu) using 
GeneTorrent (v 3.8.5a) (161). The RNAseq from the TCGA dataset was 
comprised of 302 metastatic melanoma samples and 82 primary melanomas 
(78). We compared RNAseq-derived FPKM values of KIT expression in BRAFWT 
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samples to a BRAFV600E group, where the BRAFWT group excluded BRAFV600E 
and all other BRAF-mutant melanoma samples. Gene Set Enrichment Analysis 
(GSEA) was performed using GSEA (v 2.2.0) (144,162). A rank-ordered gene list 
was generated based on Pearson correlation of the expression level of each 
gene with KIT expression in TCGA melanoma samples. Only genes with reads in 
≥90% of samples were included. The rank-ordered gene list was analyzed for 
enrichment of a set of genes at least 3-fold upregulated by overexpression of 
BRAFV600E in cultured melanocytes (143).  
 Survival analysis was performed by first sorting patients into groups with 
high (upper-most 20%) or low (lower-most 20%) BRAFWT:BRAFV600E allele ratios, 
followed by further ranking KIT mRNA expression within each group to define the 
high and low KIT groups as the upper or lower 50% of these ranked lists.  
 
Zebrafish strains and miniCoopR tumor onset assay 
The zebrafish mutant alleles used in this study include p53(zdf1) (163), 
Tg(mitfa:BRAFV600E) (135), kit(b5) (129), ednrb(b140) (129), kit(e78) (146), and 
mitfa(w2) (128). Strains were housed and cared for as approved by the 
Institutional Animal Care and Use Committee (IACUC) at the University of 
Massachusetts Medical School. miniCoopR constructs were cloned to express 
either enhanced green fluorescent protein (EGFP) or human BRAFWT under the 
mitfa promoter juxtaposed to a mitfa minigene cassette containing the mitfa 
promoter, open reading frame, and 3’ UTR. These were injected into embryos at 
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the one-cell stage along with Tol2 transposase mRNA. Fish with melanocyte 
rescue were selected as juveniles approximately two months post-fertilization 
and monitored weekly by visual inspection for exophytic tumor growth (136). 
 
In-situ hybridization 
 Tg(mitfa:BRAFV600E); p53(lf) zebrafish with dorsal anterior melanomas 
were euthanized, then stored overnight in 4% paraformaldehyde at 4°C. Samples 
were incubated in 5%, then 30% sucrose, followed by flash freezing in Tissue-tek 
O.C.T. compound (VWR) on dry ice. 20 µm transverse sections were placed on 
Superfrost Plus charged slides (Thermo-Fisher) then desiccated and frozen 
at -80°C. Digoxigenin-labeled riboprobes were synthesized using a zebrafish kita 
cDNA template transcribed with T3 or T7 polymerases for antisense or sense 
probes, respectively (MAXIscript Kit; Thermo-Fisher). Tumor samples were 
rehydrated in a series of decreasing ethanol concentrations and in 2X Saline 
Sodium Citrate (SSC). They were then incubated in 10 ug/ml Proteinase K for 3-
5 minutes and washed with water and triethanolamine (TEA) at pH 8.0. After 
incubation in an acetic anhydride/TEA solution, samples were dehydrated with 
increasing ethanol concentrations and dried before beginning an overnight 
incubation with the riboprobes at 55°C. Washes were performed with 2X SSC, 
formamide, and then samples were incubated for 30 minutes with RNAse A at 
37°C. Samples were incubated in a maleic acid blocking buffer (Roche) for 2 
hours followed by an overnight incubation with 1:1000 alkaline phosphatase-
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conjugated anti-digoxigenin antibody (Roche) at 4°C. Samples were washed with 
maleate buffer and fluorescence was detected after incubation with Fast Red 
(HNPP Fluorescent Detection Set; Roche).  
 
Mosaic analysis 
Donor blastomeres from kit(lf); Tg(mitfa:BRAFV600E); p53(lf) embryos were 
transplanted into Tg(mitfa:BRAFV600E); p53(lf); mitfa(lf) blastula-stage host 
embryos or, conversely, donor blastomeres from Tg(mitfa:BRAFV600E); p53(lf) 
embryos were transplanted into kit(lf); Tg(mitfa:BRAFV600E); p53(lf); mitfa(lf) 
blastula-stage host embryos. Host animals were raised to adulthood and 
selected for melanocyte positivity, indicating successful donor cell growth. Fish 
with melanomas that arose on the dorsal anterior region were euthanized, 
paraffin-embedded, and stained with hematoxylin and eosin to produce 
transverse sections that were analyzed for tumor cell invasion. 
 
Melanocyte scale density assay 
4- to 6-month old fish were treated for 5 minutes with the anesthetic 
tricaine methanesulfonate and epinephrine, which contracts melanosomes to the 
central cell body of melanocytes, thereby resolving overlapping cells. Scales 
were plucked from the dorsal anterior region of fish from the scale rows adjacent 
to the dorsal midline row. Scales were immediately fixed for ≥30 minutes in 4% 
paraformaldehyde. After fixation, scales were flat mounted and melanocytes 
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counted. Area was estimated by multiplying maximal antero-posterior and left-
right distances on the scale. Five scales from each of three different animals 
were used to calculate mean melanocyte density. 
 
Cell culture 
KIT knockdown experiments were performed in 888MEL cells obtained 
from the Yale SPORE in Skin Cancer. Cells were grown in F10 (Life 
Technologies 11550043) media with 5% FBS and 2% penicillin/streptomycin. KIT 
knockdown was accomplished with the pGIPZ lentiviral shRNA V3LHS_345750 
(target sequence 5' - GCATTAAAGCAGCGTATC - 3') or the TRC pLKO.1 
shRNA TRCN0000000388 (target sequence 5' - 
AAACCCAGGGCTGCCTTGGAAAAG - 3'). A non-silencing pGIPZ lentiviral 
shRNA 22-mer that contains at least 3 or more mismatches against any 
mammalian gene was used as a negative control (sequence 5’ - 
ATCTCGCTTGGGCGAGAGTAAG – 3’). Lentiviral particles were produced over 
the course of 48 hours in HEK293T cells co-transfected with the lentiviral 
packaging plasmids psPAX and PMD2.G. After harvesting, viral supernatant was 
filtered with a 0.45µm filter then mixed 1:1 in F10 media with 5% Fetal Bovine 
Serum (FBS), 2% penicillin/streptomycin, and 2-8 µg/ml Polybrene (Sigma). Cells 
were selected using 1 µg/ml puromycin for 2-4 days to establish stable cell lines. 
An identical approach was used to overexpress KIT and EGFP from pLENTI-
CMV-KIT or pLENTI-CMV-EGFP constructs in HEK293T, A375, and UACC257 
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cells, but in these cases the viral supernatant was mixed 1:1 with DMEM plus 
10% FBS and 2% penicillin/streptomycin. HEK293T, A375, and UACC257 cells 
were grown in DMEM plus 10% FBS and 2% penicillin/streptomycin. HEK293T 
transient transfections were performed with Lipofectamine 2000 (Life 
Technologies) according to the manufacturer’s protocol. 
 
BRET Assay 
BRET was performed as described by Lavoie et. al. (150). In brief, 
HEK293T cells were plated at 300,000 cells per well in six-well tissue culture-
treated plates. After 48 hours, each well was incubated in 2 ml Opti-MEM, then 
transfected with 7.5 µl Lipofectamine 2000 plus a specified combination of 
pLHCX-RLuc-CRAF (100 ng), pLPCS-V-BRAFV600E, pLPCS-V-BRAFR188L/V600E, 
pLPCS-V-BRAFWT, or pLPCS-V-BRAFR188L (0, 50, 100, 200, 300, 400, or 600 
ng), and pCDNA3.1-NRASQ61K (250 ng) or pCDNA3.1-EMPTY (250 ng) in 200 µl 
Opti-MEM. Either KIT stimulation with SCF or NRASQ61K overexpression was 
used for induction of upstream pathway activity (STIM), as indicated. 48 hours 
after transfection, cells were resuspended in 500 µl Tyrode’s buffer, then split 
onto opaque 96-well plates (Perkin Elmer 6005680). An initial reading of total 
Venus expression was taken on a PE Envision plate reader (excitation 
480±30nm, emission at 530±10nm). 10 µl of coelenterazine h (Biotium 10111-1) 
was then added automatically through the PE Envision robotic pump to a final 
concentration of 2.5 µM. BRET readings were taken using two filter sets 
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(emission 485±15nm, emission 530±10nm) 5 minutes after adding 
coelenterazine. The BRET signal was determined by calculating the 530/485 
signal ratio for a given sample and subtracting the 530/485 ratio measured when 
expressing RLuc-CRAF alone. These values were plotted as a function of the 
total 530/485 ratio (as a measurement of [Acceptor]/[Donor]) for a range of 
[Acceptor]/[Donor] concentrations, then fit with a one-site binding hyperbolic 
equation in GraphPad Prism (v 6.05). Each condition was run in biological 
triplicate, and each of these replicates was run on a separate plate in immediate 
succession to one another. Each plate was calculated separately for background 
subtraction, then all data points from the three biological replicates were 
combined to calculate Kd, referred to here as BRET50. 
 
Western Blotting 
Protein was harvested from zebrafish melanomas 2-6 weeks post-tumor 
onset by first euthanizing the fish with tricaine methanesulfonate followed by 
surgical removal of the tumor. Tumors were triturated and lysed in ice-cold RIPA 
buffer containing a cOmplete protease inhibitor tablet (Roche). Protein 
concentration was measured using the Pierce BCA Protein Assay Kit (Life 
Technologies). Samples were run on 10% polyacrylamide gels, transferred, and 
developed using fluorophore-conjugated antibodies (LI-COR). Antibodies against 
the following proteins were used: Mitfa (136); RAF-1 (c-RAF), pMEK1/2 
(S217/221), MEK1/2, p44/42 MAPK (ERK1/2), alpha-Tubulin, pAKT S473, AKT, 
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pc-KIT, c-KIT (Cell Signaling 9422, 9154, 8727, 4695, 38735, 4060, 4685, 3391, 
3308, respectively); pERK (Sigma m8159);  BRAFV600E (Spring Bioscience 
E19290); total BRAF (Millipore 10146); IRDye 800CW Donkey anti-Rabbit and 
IRDye 680RD Goat anti-Mouse (LI-COR 926-32213 and 926-68070, 
respectively). All quantitative measurements were calculated based on 
measurements from a LI-COR Odyssey Imaging System and quantified with 
Image Studio Lite (v 5.0) software. For background subtraction, a median pixel 
intensity for regions 3 pixels above and below a selected band was calculated 
and subtracted from the mean pixel intensity of that band.  
 
Growth Curves 
Cells were plated at 20,000-50,000 cells per well in 6-well plates and 
growth was assayed by resuspending and directly counting the cells on a 
hemocytometer with samples taken in biological triplicate for 6 days. Cells were 
grown in their respective media specified above, plus 0.5% FBS with either 200 
ng/ml Bovine Serum Albumin or Stem Cell Factor administered on days 1 and 4. 
 
Statistical Analysis 
Significance calculations were performed on samples collected in a minimum of 
biological triplicate. P values from two-tailed Student’s t tests were calculated for 
all comparisons of continuous variables. All further significance tests were 
performed in Graphpad Prism (v6.05). Fisher’s exact tests were used to calculate 
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P values for 2x2 contingency tables of the association of KIT expression with 
melanoma patient clinical parameters, whereas a P value for the 2x3 contingency 
table of zebrafish melanoma invasiveness was calculated by a chi-squared test. 
F-tests were used to determine significance of changes upon stimulation of 
BRET titration curves. Log-rank tests were used to calculate significance of 
changes in zebrafish tumor onset curves as well as the differences in overall 
survival of select human melanoma cohorts. A P value < 0.05 was considered 
significant. 
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Chapter III - Discussion 
Impact of our work in the field 
Alterations in MAPK pathway signaling in melanoma are critical to disease 
progression and development of inhibitor resistance. Acquisition of a BRAFV600E 
mutation ramps up MAPK activity and, given sufficient loss of tumor suppressor 
genes, can lead to disease initiation. Effective targeting of BRAFV600E with ATP-
competitive inhibitors reduces pathway activity, leading to tumor regression that 
is eventually reversed as compensatory mutations or gene expression changes 
reactivate the MAPK pathway (91). The reactivation of the MAPK pathway has 
led to attempts to target multiple members of the RAS/MAPK pathway to fully 
inhibit RAF-driven melanoma progression (164). The results of our study with KIT 
would suggest that inhibition of RTKs upstream of BRAFV600E may cause further 
activation of the MAPK pathway, given sufficient retention of BRAFWT expression 
(Fig. II.15). Although our results suggest caution against targeting RTKs in 
BRAFV600E-driven cancers, the reverse practice of stimulating RTKs would not 
necessarily be recommended by our results.  We have seen that pathway 
stimulation of BRAFV600E-mutant cells that co-express BRAFWT reduces MAPK 
pathway activation by about 20%. The resulting MAPK signaling is still 50% 
stronger than the signal arising from BRAFWT stimulation in our experimental 
system. Therefore, KIT stimulation would be unlikely to cause melanoma tumor 
regression, which requires >80% inhibition of pERK levels in BRAFV600E-driven 
melanoma (165). Furthermore, despite their relatively delayed tumor onset, 
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Tg(mitfa:BRAFV600E); p53(lf) zebrafish with wild-type kit still develop melanomas 
with 100% penetrance around 60 weeks, suggesting that, although KIT activity 
may delay tumor onset, it may not change the lifetime risk of developing this 
disease.  
 
Our studies address the long-standing question regarding what role KIT 
plays in melanoma. For several decades it has been known that the majority of 
melanomas lose KIT expression, suggesting that although KIT is required for 
melanocyte development, it is dispensable for melanoma progression and may 
indeed be beneficial to tumor growth (120-122). Multiple studies in the 1990s 
observed that KIT stimulation inhibited the growth of certain melanoma cell lines 
(124,125), yet greater attention to the role of KIT in melanoma came as activating 
mutations in KIT were found to drive melanoma formation and could be 
successfully targeted with tyrosine kinase inhibitors (117,118). Many reviews of 
melanoma genetics focus on the small fraction of melanomas with KIT activating 
mutations and simply describe KIT as a melanoma oncogene (166-169) while 
other reviews do discuss that KIT is absent in most melanomas, but they cannot 
make conclusions from previous melanoma cell line experiments as to whether 
KIT acts as a suppressor in melanoma (170,171). Our work balances the 
discussion to show that the loss of wild-type KIT contributes to the progression of 
highly common BRAFV600E-mutant melanomas. More broadly our work reinforces 
the concept that melanomas with powerful RAF-activating mutations may be 
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prone to low RTK and RAS activity. Although previous work has shown that low 
RAS-GTP levels in BRAFV600E-mutant melanomas may be attributed to the high 
SPRY feedback that results from ERK hyperactivity to sequester the GRB-SOS 
complex required for RAS activation (88), our work indicates that cancer cells 
may further benefit from genetic downregulation of RTKs as this will prevent 
induction of wild-type signaling components. 
 
A major technical challenge faced in this work was to determine 
physiological conditions of induced BRAF activation as measured by formation of 
BRAF:CRAF dimers. Our work had indicated that a key to the KIT-mediated 
reduction of BRAFV600E-induced MAPK pathway activity would be to understand 
the dynamics of RAF dimer formation in response to upstream pathway activity. 
Mutations in BRAF that disrupt its dimerization domain dramatically reduce the 
signaling capacity of BRAF (172). Additional work has shown that BRAF:CRAF 
dimerization induced by upstream stimulation is the most active and effective 
form for RAF proteins to transmit the stimulatory signal to activate MEK and 
downstream ERK (83,84). The V600E mutation renders BRAF somewhat 
immune from this dimerization requirement as it is capable of signaling as a 
monomer in the cytoplasm in a RAS-independent manner and dimerization 
disrupting mutations only mildly reduce the signaling capacity of BRAFV600E 
(90,172). While it has been reported that enforced dimerization between 
BRAFV600E and CRAF reduces the signaling capacity of BRAFV600E (153), the 
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effect of BRAFWT:CRAF dimer formation on BRAFV600E-expressing cells has not 
been previously explored. We predicted that signaling through activated BRAFWT 
would result in a lower overall MAPK pathway output due to the mixture of high 
and low kinase activity RAF species. To investigate this hypothesis, we chose to 
use a BRET assay that, unlike a more straightforward immunoprecipitation 
experiment, would allow us to study RAF dimerization dynamics in response to 
upstream pathway activity in live cells with high sensitivity. This system has been 
used to study interaction dynamics of G-protein coupled receptors (173) and has 
been previously applied to BRAF:CRAF dimerization induced by oncogenic 
KRASG12D (150). We incorporated a similar model for our experiments by titrating 
a transfection of Venus-tagged BRAF (V-BRAF) with Renilla luciferase-tagged 
CRAF (Rluc-CRAF) and co-expressing either NRASQ61K or KIT with 
supplementary SCF. We were able to successfully identify transfection conditions 
that would result in varying levels of BRAF:CRAF dimer formation. We were also 
able to confirm that the RAS-GTP-binding defective mutant BRAFR188L was 
significantly less sensitive to upstream pathway stimulation than BRAFWT, 
establishing this as a meaningful negative control. The BRET experiments were 
critical in demonstrating that the activation of BRAFWT though dimerization with 
CRAF in response to upstream pathway activity was necessary for that activity to 
cause a reduction of the MAPK pathway signaling in BRAFV600E-mutant cells. 
While the Lavoie et. al study performed large-scale BRET by using the 
inexpensive polyethylenamine as a transfection reagent and membrane-localized 
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RAF-CAAX-fusion constructs that were more prone to dimerization, we used the 
more effective, but expensive, reagent Lipofectamine with full-length protein 
constructs that were less sensitive to dimer induction. The high amount of 
transfection reagent and plasmids used for the methods of our study may 
represent a burden that would prevent use of our methods for larger scale 
analyses. More ideal transfection reagents and conditions would need to be 
found to scale-up these experiments experiments. 
 
Major issues raised by our findings 
Understanding the role a gene plays in tumor development can be highly context 
dependent. Contrary to the classic tumorigenic role of oncogenic mutant KIT, 
wild-type KIT will inhibit tumorigenesis when in the presence of a BRAFV600E 
mutation. Furthermore, our analysis of zebrafish miniCoopR tumors and clinical 
outcome in the TCGA dataset of melanoma patients indicates that KIT will only 
have a suppressive effect on BRAFV600E-mutant melanomas when a sufficient 
amount of BRAFWT is present to be activated downstream of KIT. Our work 
highlights the importance of measuring the BRAFV600E allele ratio, reinforcing 
previous analysis of TCGA thyroid cancers showing the BRAFV600E allele ratio 
correlated directly with tumor size and number of metastatic lymph nodes (174). 
The BRAFV600E allele ratio may not be the only deciding factor determining 
whether KIT should be classified as oncogenic or tumor suppressive, since it is 
possible that even in a scenario with a high BRAFWT:BRAFV600E ratio, over-
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activation of KIT through locus amplification or acquisition of an oncogenic 
mutation could still hyperactivate the MAPK pathway to levels similar or even 
greater than that achieved by monomeric, unstimulated BRAFV600E. While at 
physiological levels, KIT activation has proven to be tumor suppressive, it 
remains to be tested whether hyperactivation of KIT would have the same effect 
in vivo. 
 
Many human melanomas have low KIT expression and our proposed 
mechanism only accounts for the KIT loss in the tumors that maintain BRAFWT 
expression in BRAFV600E-mutant melanomas. Based on the TCGA melanoma 
dataset, we observed that KIT expression correlated with a significant survival 
benefit for roughly 20% of BRAFV600E-mutant melanomas that possessed 
BRAFWT:BRAFV600E ratios greater than 70%. KIT-expressing BRAFV600E-mutant 
melanoma cells may actually have greater sensitivity to low levels of BRAFWT 
expression since the UACC257 and the 888MEL cells experienced KIT-induced 
reductions of MAPK pathway signaling and cellular growth with 
BRAFWT:BRAFV600E ratios of 45% and 30%, respectively. Using this cutoff, we 
would expect KIT loss to have a suppressive role in 80% of BRAFV600E-mutant 
melanomas, accounting for roughly 30% of all melanomas. Given that many of 
the remaining fraction of BRAFWT melanomas have also lost KIT expression 
more often than expected by coincidence, we anticipate that KIT may either 
contribute to inhibition of oncogenic signaling of other MAPK pathway activators 
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such as NRAS by similarly inducing wild-type components (discussed more fully 
below), or that KIT loss may reduce stimulation of alternative growth-inhibitory 
pathways, such as the previously reported apoptosis in melanoma cell lines 
(125). 
 
As our work establishes the loss of KIT expression as an important 
promoter of melanoma progression, it is important to ask how its expression is 
regulated in cancer. The transcription of the KIT gene has been shown to be 
regulated by the transcription factor activator protein 2 (TFAP2) through direct 
interaction with at least three distinct TFAP2 target sites in the KIT promoter 
(147). The frequent loss of this transcription factor in melanoma cell lines 
contributes to the loss of KIT expression in human melanoma (147,148). 
Additionally the KIT locus on chromosome 4 has been reported to be recurrently 
deleted in a series of 123 short term melanoma cultures (27). Another mode of 
transcriptional regulation of KIT in melanoma was recently discovered as it was 
identified in a genome-wide promoter methylation screen that the KIT locus was 
among the few transcription start sites that were hypermethylated in all four of 
the human melanoma cell lines tested, but in neither of the two cultured 
epidermal melanocyte cell lines (123). Further investigation revealed that 0/2 
benign nevi contained KIT promoter hypermethylation, whereas 57/151 (38%) of 
melanoma samples comprised of cell lines, primary, and metastatic melanoma 
contained KIT promoter hypermethylation that correlated positively with KIT 
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mRNA expression (123). While loss of transcriptional regulatory factors, copy 
number loss, and promoter hypermethylation provide clues to how KIT 
expression is lost in human melanomas, it remains unknown why zebrafish 
melanomas retain expression of Kit. The zebrafish orthologue Tfap2a is known to 
positively regulate kit expression in zebrafish, but only partially as additional 
knockdown of its homologue Tfap2e is required to eliminate kit mRNA expression 
at late stages of embryonic development (175). Given that tfap2a is located on 
zebrafish chromosome 24 in a region that is not recurrently deleted and tfap2e is 
located on chromosome 19 of fish, which is the chromosome containing the 
mitfa:BRAFV600E transgene that has been observed to be recurrently amplified in 
zebrafish melanomas (unpublished data), it is likely that these factors promote 
the continued expression of zebrafish kit during tumorigenesis. Additionally the 
kit locus on chromosome 20 (kita) is adjacent to a recurrently amplified region 
that should further promote kit expression in zebrafish melanoma (unpublished 
data). 
 
Remaining questions and future directions 
 The primary observation of our mechanistic experiments reports that 
pathway stimulation from either KIT stimulated with SCF or from NRASQ61K will 
cause reduced MAPK pathway output in BRAFV600E-mutant cells given the 
presence of RAS-inducible BRAFWT. While an increase in the number of active 
kinase molecules in a cell would be predicted to raise its signaling output, the fact 
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that we observe a decrease in overall signaling though MEK suggests that the 
mixture of low- and high-activity kinase species are likely competing for a limited 
number of substrates to enact cellular signaling. Among the well characterized 
components of the MAPK signaling pathway, one could propose that BRAFWT 
and BRAFV600E could be competing with each other for access to CRAF, KSR, or 
MEK (Fig. II.15). CRAF acts as the direct recipient of BRAF kinase activity upon 
RAS-induced dimerization where the activation loop of CRAF becomes 
phosphorylated permitting CRAF to further phosphorylate and activate MEK (84). 
Although BRAFWT associates poorly with CRAF in unstimulated cells, BRAFV600E 
has been previously reported to co-IP with CRAF in the absence of 
stimulation(153), agreeing with our unstimulated BRET titration curves for 
BRAFV600E and BRAFWT having a BRET50 of 3.251 or 4.473, respectively, 
suggesting a higher latent background association between BRAFV600E and 
CRAF. Nevertheless, if activation of BRAFWT were to compete CRAF away from 
BRAFV600E, the V600E isoform can still activate MEK as a monomer or 
homodimer independently from CRAF (172). A more thorough investigation could 
be performed overexpressing CRAF to a level where it could no longer act as a 
limiting component between BRAF isoforms to test whether this abundance of 
CRAF could eliminate the ability of stimulated BRAFWT to inhibit BRAFV600E 
activity.  
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Alternatively BRAFWT could compete for binding to the MAPK pathway 
signaling scaffold KSR, which facilitates BRAF:CRAF dimerization and 
interaction with MEK (176). An absence of KSR expression results in poor signal 
transduction through BRAF:CRAF dimers induced by oncogenic RAS, while 
overexpression of KSR can compete with CRAF for binding to BRAF dimerization 
induced by either RAF inhibitors or RAS oncogenic mutants leading to reduced 
activity of BRAF and reduced activation of CRAF (158). If we extend these 
results to our model, we may consider that activated BRAFWT could recruit some 
combination of KSR and CRAF away from BRAFV600E, reducing its ability to 
complex with and activate MEK. While the inhibition of the KSR:MEK interaction 
has been shown to sensitize cells expressing BRAFWT and oncogenic RAS to 
MEK inhibition, this was shown to have no effect on cells expressing BRAFV600E, 
suggesting that BRAFV600E oncogenic activity persists regardless of disrupted 
KSR scaffolding (177).  
 
Finally we may consider the possibility that MEK itself is the limiting factor 
of this system and an increased proportion of MEK would be activated by low 
kinase activity BRAFWT under stimulating conditions. This could be investigated 
by additional BRET experiments testing for the dynamic changes in 
BRAFWT:MEK and BRAFV600E:MEK interactions as increasing amounts of 
BRAFWT are expressed in stimulated and unstimulated cells. In such 
experiments, a limiting role of MEK would be revealed as the increasing amounts 
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of BRAFWT overexpressed in BRAFV600E-mutant cells would be associated with a 
gain of BRAFWT:MEK interactions and concomitant loss of BRAFV600E:MEK 
interactions that would correlate with decreased MEK activation. Such 
experiments could also be expanded to express MEK at levels where it would no 
longer act as a limited factor to then see whether BRAFWT activation would no 
longer inhibit BRAFV600E activity. 
 
We have argued that it is unlikely for the increased MAPK pathway 
activation seen in BRAFV600E-mutant cells with KIT knockdown to be due to 
negative feedback from ERK-dependent feedback phosphorylations on BRAF or 
induction of the ERK-phosphatase DUSP family. An additional form of negative 
feedback from ERK comes from the sprouty (spry) family of RTK inhibitors 
SPRY1 or SPRY2. It has been previously shown that the spry genes are 
upregulated in response to the high MAPK activity induced by BRAFV600E to 
cause those cells to have low steady-state RAS-GTP levels (88). It is thus 
possible that SPRY activity actually helps preserve high MAPK activity by 
restraining RTK-mediated activation of BRAFWT allowing BRAFV600E to signal in a 
RAS-independent manner. SPRY could play an inhibitory role in KIT-positive 
BRAFV600E homozygous mutant cell lines where RTK activity would be predicted 
to promote BRAFV600E signaling. 
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This concept of upstream pathway activity driving competition between 
wild-type and oncogenic variants of BRAF provides an additional explanation for 
the observation that BRAF and NRAS mutations are almost always mutually 
exclusive in melanoma (78,178). Although it remains possible that this mutual 
exclusivity is simply due to the epistatic relationship of BRAF and NRAS, it has 
been proposed that the co-occurrence of their mutations could lead to synthetic 
lethality through induction of senescence (178,179). Due to the nature of RAF 
dimer formation in response to RTK and RAS activity (84,150,172), pathway 
stimulation from either KIT or NRAS could reduce BRAFV600E output by 
stimulating low-kinase-activity BRAF isoforms to enter into dimers with CRAF 
and compete for available signaling components. Indeed our data supports the 
concept that NRASQ61K negatively affects BRAFV600E signaling through activation 
of BRAFWT similarly and more robustly than the negative effect from KIT activity 
(compare Fig II.9d and II.10c). A BRAFV600E-mutant tumor may gain a survival or 
proliferative advantage by diminishing KIT or NRAS activities so that BRAFV600E 
could act to freely drive MEK/ERK activation.  
 
In addition to mutual exclusivity of BRAF and KIT or BRAF and NRAS 
mutations, we also observe in the TCGA melanoma dataset that KIT and NRAS 
mutations rarely co-occur (2/89) and KIT expression is also generally low in 
these tumors, similar to the low expression observed in BRAFV600E-mutant 
melanoma - 9.9 ± 19.9 and 13.6 ± 25.2 KIT mRNA FPKM values ± SEM for 
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NRAS-mutant and BRAFV600E-mutant melanomas, respectively compared to 34.2 
± 6.8 for all BRAFWT/NRASWT melanomas. It remains to be tested in vivo whether 
the loss of KIT would contribute to NRAS-mutant melanoma as they do to BRAF-
mutant melanoma, though one could propose a similar mechanism of action as 
we have for BRAF where KIT would activate low-activity wild-type NRAS that 
would lead to reduced activation of the MAPK pathway. Indeed, deletion of a 
wild-type KRAS allele (KRASWT) has proven to increase the rate of lung 
tumorigenesis driven by KRASG12D and overexpression of KRASWT caused a 
reduction of pERK levels in KRAS mutant cells (160,180). While it is not clear 
how wild-type copies of RAS genes inhibit their oncogenic counterparts, it has 
been proposed that they compete for downstream signaling apparatus, promote 
differentiation, or stimulate alternative cellular functions that protect against 
oncogenesis (160,180). Additional zebrafish melanoma models could potentially 
be generated to directly test whether Kit inhibits NRAS-driven melanomas or 
whether other RTKs that play a significant role in melanoma, such as EGFR, may 
also act to suppress BRAF or NRAS-driven melanomas. 
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Appendix I – KIT promotes adult zebrafish melanocyte regeneration 
 
Introduction 
 In addition to the important role KIT plays to promote melanocyte development, 
KIT also plays a critical role in maintaining adult melanocytes during the 
regenerative process (181). The zebrafish makes an ideal system for studying 
the contribution of KIT to melanocyte regeneration as several methods to ablate 
and regenerate melanocytes in adult animals have already been established. 
Zebrafish will regenerate their melanocyte stripe on their caudal fins after 
amputation and adult fish will also regenerate the melanocyte stripes that 
become ablated on the side of the fish after treatment with the copper chelator 
neocuproine (NEO) (182-184). Kit has been shown to play an important role in 
melanocyte regeneration after caudal fin resection where the kit(lf) (either the 
kit(b5) allele used in our work or a kit temperature sensitive allele (kit(ts)) mutant 
zebrafish will regenerate their melanocytes 20 days after amputation, whereas 
wild-type fish only require 5 days (182,183). This delay in melanocyte 
regeneration can be rescued in a background overexpressing RAS from a heat 
shock promoter, demonstrating the epistatic nature of KIT and RAS is conserved 
in zebrafish (185). Experiments performing a clonal rescue of melanocytes after 
4-hydroxyanisol (4-HA) mediated ablation in zebrafish embryos concluded that 
kit(ts) animals were deficient in establishment of melanocyte stem cells (MSC) 
due to the decreased rate of Tg(fTyrp1:GFP) transgene incorporation by Tol2 
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transposase into kit(ts) animals, which may indicate presence of fewer MSCs 
(186). Given the imprecise nature of using transgene incorporation to estimate 
the density of MSCs and the recent development of a method by Dr. Sharanya 
Iyengar in our lab to fluorescently label melanocyte progenitor cells with a 
nuclear localization sequence-tagged EGFP (NLS-EGFP) to perform lineage 
tracing after NEO-mediated ablation (187), we aimed to test whether Kit also 
assisted regeneration of stripe melanocytes in this system, which could lead to a 
more definitive mechanism of how Kit is affecting regeneration through the use of 
lineage tracing. Prior to crossing kit(lf) mutants into the Tg(mitfa:NLS-EGFP) line, 
we first sought to determine whether we could reproduce the reported 
regeneration defect upon fin amputation and determine whether there was a 
similar regeneration defect post-NEO treatment. We also aimed to determine 
whether BRAFV600E could suppress the KIT regeneration defect similarly to how it 
suppresses KIT melanocyte developmental defects. We found that although 
Tg(mitfa:BRAFV600E) zebrafish experienced normal melanocyte regeneration, 
kit(lf) zebrafish experienced decreased regeneration and kit(lf); 
Tg(mitfa:BRAFV600E) double-mutant zebrafish experienced increased 
regeneration either post-caudal fin amputation or post-NEO treatment. This 
suggests that Kit signaling promotes proper functioning of melanocyte stem cells 
and that the synergistic effect of kit loss in BRAFV600E-mutant cells that increased 
BRAFV600E activity observed in tumors could be present within the melanocyte 
stem cells. 
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Results 
We amputated caudal fins to approximately two-thirds of their original length in 
AB, Tg(mitfa:BRAFV600E), kit(lf), and kit(lf); Tg(mitfa:BRAFV600E) backgrounds. 
After 17 days we quantified percentage area regeneration and found that while 
the AB, Tg(mitfa:BRAFV600E), and kit(lf) animals all regenerated 80-90% of the fin 
area that had been lost, kit(lf); Tg(mitfa:BRAFV600E) animals only regenerated 
approximately 72% of the original fin area and experienced severe ulceration that 
was unique to the kit(lf); Tg(mitfa:BRAFV600E) genotype (App. I.1A, I.1B). As 
anticipated, the AB, and Tg(mitfa:BRAFV600E) animals successfully regenerated 
all of their pre-amputation melanocytes, whereas kit(lf) animals experienced a 
severe deficit having regenerated only 18% of their melanocytes by day 17 (App 
I.1A, I.1C). The kit(lf); Tg(mitfa:BRAFV600E) double mutant animals partially 
restored the regeneration defect of the kit(lf) animals by regenerating 55% of 
their original melanocyte total (App I.1A, I.1C). These results support the 
conclusions that KIT and BRAF do act in the same pathway to affect melanocyte 
regeneration, though full regeneration may be hindered by the poor tissue 
regeneration of kit(lf); Tg(mitfa:BRAFV600E) animals. We performed a similar 
experiment observing a separate population of stripe melanocytes on the sides of 
the fish after NEO-mediated ablation of melanocytes. 
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App. I.1 
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App. I – The defective melanocyte regeneration after caudal fin amputation 
in kit(lf) animals is partially rescued in kit(lf); Tg(mitfa:BRAFV600E) animals. 
A) Representative images of zebrafish caudal fins before, immediately after, 7, 
and 19 days after amputation. Magnification provided for the inset on day 19 
images. B) Quantification of area regeneration calculated for each fish by 
comparing the final area to pre-amputation size. C) Quantification of melanocyte 
regeneration calculated for each fish by comparing the final melanocyte count to 
pre-amputation counts. n = 8 for each group. *P value < 0.05, **P value < 0.01, 
***P value < 0.001; Student’s t test. 
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App I.2 
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App. II – The defective melanocyte regeneration after neocuproine 
treatment in kit(lf) animals is partially rescued in kit(lf); Tg(mitfa:BRAFV600E) 
animals. 
A) Representative images of zebrafish intermediary stripes immediately ventral to 
the dorsal fin before, 7, and 22 days after neocuproine treatment. Magnification 
images provided for the inset on day 19 images. Note that the black and white 
images have yellow, green, blue, and cyan color values converted to gray for 
visualization purposes. Original images used for manual quantification of 
melanocytes. B and C) Quantification of melanocyte regeneration calculated for 
each fish by comparing the final melanocyte count to pre-treatment count for 
either DMSO (B) or NEO (C). *P value < 0.05, **P value < 0.01, ***P value < 
0.001; Student’s t test. 
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 Upon treating animals from the four genotypes with either DMSO or NEO, 
we observed a significant clearing of melanocytes in all genotypes within 7 days 
of NEO treatment, whereas DMSO had no effect on melanocyte number (App. 
I.2A, I.2B). AB animals regenerated 43% more melanocytes than they had prior 
to treatment and Tg(mitfa:BRAFV600E) animals regenerated an equivalent 
number, though with greater variability as two animals failed to regenerate more 
than 70% of their original melanocytes (App. I.2C). The kit(lf) animals 
consistently regenerated only 70% of their melanocytes, while the kit(lf); 
Tg(mitfa:BRAFV600E) animals hyper-regenerated their melanocytes, growing 
140% more melanocytes than they had prior to treatment, but again with high 
variability (App. I.2C). The kit(lf) regeneration pattern produced entire areas of 
the animal that were devoid of melanocytes (App I.2A) and the regions with 
melanocytes grew back with lower density than prior to treatment.  kit(lf); 
Tg(mitfa:BRAFV600E) animals also experienced this patchy melanocyte 
regeneration pattern (App. I.2A), but the restored patches grew with particularly 
high melanocyte density. These experiments confirm the role of Kit in melanocyte 
regeneration and further support the enhanced activity of BRAFV600E that we 
have proposed to occur in kit(lf) mutant animals.  
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Discussion 
This work reaffirms the important role Kit plays in melanocyte regeneration in the 
fin and confirms that Kit plays a similarly important role during melanocyte 
regeneration in the stripes on the side of the fish. Furthermore, it is compelling 
that while BRAFV600E alone had a minimal effect on regeneration after fin 
amputation or after NEO treatment, the kit(lf) allele synergized with the 
Tg(mitfa:BRAFV600E) transgene to promote hyper-melanocytic growth in 
regenerating zebrafish. Thus, it appears that whatever pathway of melanocyte 
stem cell development and recruitment is affected by Kit is also affected similarly 
by BRAFV600E, but the impact of BRAFV600E is enhanced in the absence of Kit 
activity. This result is in line with our findings in chapter II where we identified that 
MAPK pathway activation downstream of BRAFV600E-mutant cells is enhanced in 
the absence of KIT.  
 
 The defective fin regeneration of kit(lf); Tg(mitfa:BRAFV600E) animals after 
caudal fin amputation remains a surprise with no obvious mechanism, particularly 
given the lack of fin regeneration defects among kit(lf) or Tg(mitfa:BRAFV600E) 
animals. It has recently been reported that a heightened state of inflammation 
due to epithelial il1b expression inhibits fin fold regeneration in zebrafish embryos 
and BRAFV600E has been previously associated with chronic inflammatory states 
in Erdheim-Chester disease (188,189). It seems possible that BRAFV600E-
expressing cells may induce a localized inflammatory state that could inhibit fin 
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regeneration and that kit(lf) mutants are either highly susceptible to this 
inflammation or that BRAFV600E is simply hyperactive in a kit(lf) background. A 
mechanism to explain this phenotype will require additional experimentation. 
 
 It remains unclear how KIT and BRAF are affecting melanocyte 
regeneration. Due to the patchy pigmentation pattern of kit(lf) animals after 
regeneration from NEO treatment, it is possible that a fraction of melanocyte 
progenitor cells have died or simply fail to be activated during regeneration. The 
decreased density of melanocytes in the regenerated areas further suggests that 
even progenitor cells that are stimulated to regenerate are still deficient in the 
amount of new melanocytes they are able to produce. The kit(lf); 
Tg(mitfa:BRAFV600E) animals also displayed patchy melanocyte rescue, but had 
high density melanocyte growth within rescued patches. It is thus suspected that 
the defect that occurs in activated kit(lf)-mutant progenitor cells is rescued by 
BRAFV600E and thus distinct from the defect causing the patchy regeneration 
pigment pattern. To better ascertain what mode of regeneration has been 
affected by Kit, we can consider recent work from our lab that found a population 
of unpigmented melanocyte precursor cells that can be labeled by the transgenic 
Tg(mitfa:NLS-EGFP) construct (187). The precursor cells remain dormant until 
stimulated due to melanocyte ablation, which causes them to enter one of 
several pathways to reconstitute zebrafish stripe-associated melanocytes. 
Among the progenitors that respond to regenerate melanocytes, they may 1) 
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directly differentiate to produce one melanocyte, 2) symmetrically divide to 
produce two daughter progenitor cells, or 3) asymmetrically divide to produce a 
progenitor cell and a melanocyte. Wild-type AB fish overwhelmingly utilize the 
direct differentiation and symmetric division pathways by 45% and 47% of their 
available progenitor cells upon ablation. Only 7% of progenitors utilized 
asymmetric division. Use of this system in the future within the kit(lf) and kit(lf); 
Tg(mitfa:BRAFV600E) backgrounds should reveal whether these animals have 
been affected in melanocyte progenitor establishment, or whether one of these 
three modes of regeneration has been affected.  
 
Materials and Methods 
Fin amputation experiments 
Animals were anesthetized in tricaine and melanocyte constriction was promoted 
by treating fish with 1 mg/ml epinephrine for 5 minutes prior to imaging. 
Amputation was performed after the first round of imaging by making a vertical 
incision approximately 1/3rd into the width of the caudal fin posterior to the caudal 
peduncle. Animals were monitored with additional rounds of anesthetization and 
epinephrine treatment with imaging on days 7, 17, and 19. Total area was 
calculated by drawing a region of interest around the fin in ImageJ software and 
the melanocytes were counted by hand-placing counting pins at each 
melanocyte, also in ImageJ. 
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Neocuproine treatment 
Anesthetization, epinephrine treatment, and image analysis was performed as in 
the fin amputation experiments described above, but Photoshop was used 
instead of ImageJ. Neocuproine treatment was performed as previously 
described (187) by incubating fish overnight in fish water with 750 nM 
neocuproine plus 0.0075% DMSO.  
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Appendix II – Establishment of an accelerated onset zebrafish melanoma 
model 
Introduction 
Large-scale chemical or genetic screening in cell lines can reveal novel cancer 
generating mechanisms and therapeutic targets (190,191). This standard method 
of screening in tissue culture permits a massive number of compounds or targets 
to be evaluated that can identify many genuine cancer-associated pathways and 
therapies, but may fail to find chemicals that are bioavailable and capable of 
affecting pathways that help initiate tumorigenesis in-vivo, such as a metabolic 
re-wiring to accommodate to a certain niche or immune-evasion techniques. 
Autochthonous tumor development in zebrafish represents a promising model 
system for screening due to the high number of animals that can be produced, 
their relatively small size, and ease of genetic manipulation. Previous chemical 
screens in zebrafish have largely focused on phenotypes that can be identified 
early in development, such as the protection of neuromast hair cells from 
antibiotic exposure at 5 dpf, or the abnormal oncogene-induced hematopoietic 
progenitor cell differentiation at 12-16 hours post fertilization (hpf) (192,193). 
Zebrafish have been successfully used to screen for melanoma modifying 
compounds by observing the effect of approximately 2000 compounds from the 
BIOMOL 480 and LOPAC1280 libraries on neural crest development of 5 hpf 
embryos (52). This screen identified a compound similar to Leflunomide that 
inhibits the activity of dihydroorotate dyhydrogenase (DHODH) to thus inhibit 
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transcriptional elongatation of genes essential for neural crest development and 
melanoma progression. This discovery led to the conduction of a phase I/II 
clinical trial (NCT01611675) to test for a synergistic effect between Lefluonomide 
and Vemurafenib in BRAFV600E-mutant melanoma. 
 
 Screening for compounds or genes that directly inhibit melanoma 
formation in zebrafish is challenging due to the fact that Tg(mitfa:BRAFV600E); 
p53(lf) zebrafish do not develop melanomas until adulthood with a median onset 
around 8 months, making large-scale screening unfeasible. The miniCoopR 
system restores and overexpresses the melanoma oncogene mitfa, but only 
accelerates melanoma onset to a median of 4 to 5 months. One potential factor 
restraining tumorigenesis in these systems is the weak embryonic melanocyte 
oncogene expression possible from the 2.1 kb mitfa promoter used in this system 
(135,136). We worked to develop an early-onset zebrafish melanoma model that 
would develop a larval phenotype or potentially yield tumorigenesis prior to 
metamorphosis to facilitate large-scale screening experiments.  
 
One possibility to achieve strong, early oncogene expression would be to 
conditionally activate the ubiquitin promoter by melanocyte-specific CRE 
expression. A “ubiswitch” promoter cassette has been previously developed that 
contains the highly active ubiquitin promoter followed by a GFP open reading 
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frame (ORF) flanked by LoxP sites and an mCherry ORF that remains un-
transcribed unless the GFP ORF and its stop sequence are removed by CRE 
recombinase activity (194). We reasoned that we could use this system to drive 
selective oncogene expression, in place of mCherry, with CRE driven to express 
in the melanocytes by the mitfa promoter. Upon establishment of CRE and 
Ubiswitch lines, they could be maintained as healthy populations and then 
crossed to yield a high number of offspring with early, strong, melanocyte-
specific oncogene expression from the ubiquitin promoter (App. II.1). 
 
We established two transgenic lines, Tg(Ubiswitch:NRASQ61K); p53(lf); 
mitfa(lf) and Tg(mitfa:CRE); p53(lf), that did develop CRE-activated hyper-
melanocytic growth in 90% of offspring within 4 days of age. Lethality was 
observed in 100% of animals after 5 weeks and this was determined to be a 
melanocyte-independent, off-target effect after lethality was again observed by 
breeding the transgenic lines in a mitfa(lf) background. We developed an 
alternative CRE line using a linearized miniCoopR-CRE construct that had 
improved survival, but no larval phenotype, ultimately leading us to reject either 
of these models as feasible screening systems. This work demonstrates both the 
advantages and challenges of using zebrafish for screening experiments of 
autochthonous tumor development. 
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Results 
To create a model system that would produce a large number of offspring that 
would rapidly develop melanomas for future screening purposes, we injected 
single cell p53(lf) embryos with a Tg(mitfa:CRE) construct juxtaposed to a GFP 
open reading frame driven by the heart tissue-specific cardiac myosin light chain 
(cmlc) promoter (195). We identified heart GFP-positive embryos, raised them to 
adulthood, then screened F1 animals by outcrossing and searching for offspring 
that were heart-GFP-positive to identify founder strains that possessed germline 
transgene integration. We obtained the ubiswitch:mCherry zebrafish line (194) 
from Dr. Christian Mossiman to test the efficacy of our CRE line (App. II.1). Upon 
establishment of stable transgene expressing founder lines, we validated the 
activity of our CRE-switch system by crossing animals heterozygous for the CRE 
or Ubiswitch transgenes to yield offspring that had no transgenes, were CRE-
positive, Ubiswitch-positive, or CRE/Ubiswitch-positive. We initially performed 
this cross with Tg(ubiswitch:mCherry)/+ zebrafish and observed that 
Tg(mitfa:CRE) /+; Tg(ubiswitch:mCherry) /+ double mutant offspring, easily 
identifiable by their respective combination of heart and full body GFP-positivity, 
were the only offspring siblings that presented robust mCherry expression (App. 
II.2A). The mCherry expression did appear in melanocytes, most highly visible 
after epinephrine treatment to induce constriction of melanosomes to the center 
of melanocytes, leaving the appearance of an mCherry halo pattern around 
melanosome pigment clusters (App. II.2Aiv). While no mCherry expression was 
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detected in embryos lacking the mitfa:CRE transgene, there was apparent off-
target effects in Tg(mitfa:CRE) /+; Tg(ubiswitch:mCherry) /+ double mutant animals 
where mCherry expression was visible in non-pigmented cells, possibly 
xanthophores or other embryonic cell types where the mitfa promoter may have 
sufficient activity to drive CRE expression (App. II.2A). 
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App II.1 
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App. II.1 – Ubiswitch system for driving strong melanocyte-specific 
transgene expression. 
The Tg(ubiswitch:mCherry) line represented here would appear to have whole 
body GFP-positivity, compared to the Tg(mitfa:CRE) line which expressed heart-
specific GFP under a juxtaposed cmlc:GFP cassette. When bred together, the 
offspring of these lines would have full body-GFP, heart-GFP, and mCherry-
melanocytes due to the melanocyte-specific CRE recombination yielding 
mCherry expression. For tumorigenic assays, the mCherry open reading frame 
would be replaced with open reading frames for BRAFV600E or NRASQ61K. 
 
 While establishing the functional CRE stable line, we simultaneously 
developed Tg(ubiswitch:BRAFV600E) /+ and Tg(ubiswitch:NRASQ61K)/+ lines and 
established all CRE and Ubiswitch lines in a p53(lf) homozygous background to 
facilitate tumor development. BRAF and NRAS are the two most frequently 
mutated genes in human melanomas and thus their products would make 
meaningful targets for discovery of genetic cooperating events in melanoma or 
identification of novel inhibitors (78). We proceeded to cross the Tg(mitfa:CRE) 
lines with the Tg(ubiswitch:BRAFV600E) /+ and Tg(ubiswitch:NRASQ61K)/+ lines. 
Unfortunately, Tg(mitfa:CRE) /+; Tg(ubiswitch:BRAFV600E) /+ embryos showed no 
phenotype of melanocyte hyper-proliferation and attempts to detect heightened 
BRAF expression through in-situ hybridization were unsuccessful (data not 
shown); however, Tg(mitfa:CRE) /+; Tg(ubiswitch:NRASQ61K) /+ animals developed 
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increased numbers of dorsal head melanocytes by 4 dpf (App. II.2B, II.2C). 
These animals also contained melanocytes that had migrated into muscle 
segments, where this was almost never seen in siblings that contained only a 
single transgene (App. II.2D).   
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App. II.2 
  
126 
 
App. II.2 – Generation of Tg(mitfa:CRE); Tg(Ubiswitch) transgenic animals 
yields functional melanocyte-specific CRE activity. 
A) Siblings from a cross of Tg(mitfa:CRE)/+ (containing heart-GFP) and 
Tg(ubiswitch:mCherry)/+ (containing full body-GFP) were sorted according to 
GFP status. A GFP (Aiii) or mCherry (Aiv) magnification of the dorsal head region 
of a CRE/ubiswitch double heterozygote displays melanocyte-positive mCherry 
expression. Scale bars = 1 mm (Aii) and 0.25 mm (Aiv) B) Dorsal head region 
images from 4 day old embryo siblings heterozygous for the indicated 
transgenes. C) Quantification of dorsal head melanocytes comparing wild-type 
AB fish with Tg(mitfa:CRE)/+; Tg(ubiswitch:NRASQ61K)/+, labelled here as “CRE 
NRASQ61K”. ****P value < 0.001; Student’s t test. D) Profile images of sibling 
embryos from panel B illustrating the mis-migration of melanocytes in 
Tg(mitfa:CRE)/+; Tg(ubiswitch:NRASQ61K)/+ animals. Scale bar = 1 mm. 
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We followed the development of the Tg(mitfa:CRE)/+; 
Tg(ubiswitch:NRASQ61K)/+ double mutant animals and compared to AB animals 
during the first three weeks of development, prior to metamorphosis while the 
animals remain a size that could potentially facilitate large-scale screening. We 
observed that melanocyte populations of Tg(mitfa:CRE)/+; 
Tg(ubiswitch:NRASQ61K)/+; p53(lf) animals continued to proliferate and infiltrate 
tissues during this time (App. II.3A). Furthermore, Tg(mitfa:CRE)/+; 
Tg(ubiswitch:NRASQ61K)/+; p53(lf) animals experienced remarkably poor 
survivorship, where no animals survived juvenile-to-adult morphogenesis stage 
to live past 5 weeks of age, whereas their siblings with inheritance of individual 
transgenes had normal survival during this time period (App. II.3B). We 
considered that if the early-death phenotype was caused by melanocyte hyper-
proliferation, this could make a promising model for large-scale screening as the 
animals were small enough to raise in micro-plates and had a phenotype that 
would be easy to score by simply observing survival past 5 weeks. 
 
To test whether the death was attributable to melanocyte hyper-
proliferation, we crossed our transgenic lines into a mitfa(lf) background to 
eliminate melanocyte development. To our surprise, although the 
Tg(mitfa:CRE)/+; Tg(ubiswitch:NRASQ61K)/+; p53(lf); mitfa(lf) animals appeared 
normal during embryonic development (App II.3C), they experienced a similar 
early-death onset at around 5 weeks of age (App. II.3D). This suggests that CRE 
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may be activating NRASQ61K expression in tissues other than melanocytes, 
making this early-death phenotype unusable for screening melanoma-modifying 
molecules or genes.  
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App. II.3 
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App. II.3 – Development of pigmented lesions and early-death apparent in 
Tg(mitfa:CRE)/+; Tg(ubiswitch:NRASQ61K) /+; p53(lf) animals. 
A) Dorsal and profile views of AB and Tg(mitfa:CRE)/+; Tg(ubiswitch:NRASQ61K) /+ 
larvae and juvenile animals. B) Survivorship of siblings generated from a cross of  
p53(lf), Tg(mitfa:CRE)/+; p53(lf) and Tg(ubiswitch:NRASQ61K) /+; p53(lf), then 
sorted according to GFP fluorescence as in figure App. II.2 for being p53(lf), 
Tg(mitfa:CRE)/+; p53(lf) (CRE; p53(lf)), Tg(ubiswitch:NRASQ61K) /+; p53(lf) 
(NRASQ61K; p53(lf)), or Tg(mitfa:CRE)/+; Tg(ubiswitch:NRASQ61K) /+; p53(lf) (CRE; 
NRASQ61K; p53(lf)). P value calculated comparing NRASQ61K; p53(lf) and CRE; 
NRASQ61K; p53(lf) animals; Log rank test. C) Representative profile images of 4 
dpf Tg(mitfa:CRE)/+; Tg(ubiswitch:NRASQ61K) /+; p53(lf) and Tg(mitfa:CRE)/+; 
Tg(ubiswitch:NRASQ61K) /+; p53(lf); mitfa(lf) animals. D) Survivorship curves for 
AB, mitfa(lf), Tg(mitfa:CRE)/+; Tg(ubiswitch:NRASQ61K) /+; p53(lf) (CRE; 
NRASQ61K), and Tg(mitfa:CRE)/+; Tg(ubiswitch:NRASQ61K) /+; p53(lf); mitfa(lf) 
(CRE; NRASQ61K; mitfa(lf)) animals.  
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 To establish a novel melanoma model that would have alternative CRE 
expression patterns and increase the copy number of the melanoma oncogene 
mitfa, we prepared a linearized miniCoopR-CRE construct, where CRE is still 
expressed under the mitfa promoter, but linearization of the construct should 
permit for in-vivo concatemerization prior to transgene integration, resulting in 
animals that have multiple copies of mitfa and CRE (App. II.4A). We injected this 
construct into p53(lf); mitfa(lf) embryos, bred F1 animals with melanocyte rescue, 
and identified several founder animals whose offspring grew melanocytes, 
indicating successful germline transgene integration. The Tg(miniCoopR:CRE); 
p53(lf); mitfa(lf) animals developed reduced numbers of melanocytes (App. II.4B 
and compare column 3 of App. II.2C with column 1 of App. II.4C) and the 
inclusion of a Tg(ubiswitch:NRASQ61K) transgene made no difference to 
melanocyte development in 4 dpf embryos (App. II.4B and II.4C). While the 
Tg(miniCoopR:CRE)/+; Tg(ubiswitch:NRASQ61K) /+; p53(lf); mitfa(lf) animals did 
not experience an early death phenotype as severe as that observed in 
Tg(mitfa:CRE) animals, they did have a median survival of 16 weeks and were 
prone to formation of pigmented melanocytic lesions with a median onset of 7 
weeks (App. II.4D). At early stages, these lesions were similar in appearance to 
the reported f-nevi that form in Tg(mitfa:BRAFV600E) mutant fish that lack any 
additional cancer causing mutations (135). The lesions in Tg(miniCoopR:CRE)/+; 
Tg(ubiswitch:NRASQ61K) /+; p53(lf); mitfa(lf) animals progressed during weeks 4-9 
with a spreading growth pattern that did not typically develop the large exophytic 
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tumor masses of Tg(mitfa:BRAFV600E); p53(lf) zebrafish (App. II.4D) (135). 
Although the lesions tended not to grow up above the surface of the fish, their 
effect on animal health was readily apparent as lesion-bearing animals became 
sclerotic, stunted, and experienced poor survival (App. II.4D). It remains to be 
tested whether a mitfa(lf) mutation would suppress the poor survival of these 
animals.  
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App. II.4 
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App. II.4 – Development of an alternative CRE driver line with a linearized 
miniCoopR-CRE construct. 
A) Scheme for developing a stable melanocyte-restricted CRE line where the 
miniCoopR vector is linearized and injected into p53(lf); mitfa(lf) animals, raised 
to adulthood and bred to additional p53(lf); mitfa(lf) animals to identify founders 
with germline integrations of the linearized vector. B) Dorsal head images of 
representative 4 dpf Tg(miniCoopR:CRE)/+; p53(lf); mitfa(lf) (“CRE”) and 
Tg(miniCoopR:CRE)/+; Tg(ubiswitch:NRASQ61K); p53(lf); mitfa(lf) 
(“CRE+NRASQ61K”), scale bars = 1 mm, with accompanying quantification in C. 
Significance tested by Student’s t test. D) Progression of lesion formation from 4 
to 9 weeks of age and associated quantification of lesion-free survival of 
CRE+NRASQ61K animals plus overall survival of CRE and CRE+NRASQ61K 
animals. 
Discussion 
The Ubiswitch-NRAS early tumor model represents a potential paradigm shift of 
what is possible in screening for modifiers of autochthonous tumor development, 
yet also shows the difficulty in establishing an appropriate model for such a 
screen. We were able to achieve remarkable early hyper-melanocytic growth in 
Tg(mitfa:CRE)/+; Tg(ubiswitch:NRASQ61K)/+; p53(lf) animals, where 90% of 
animals had higher than average numbers of melanocytes by 4 dpf, although we 
were unable to confirm whether the pigmented lesions that later grew from this 
hyper-pigmentation represented genuine melanomas prior to the animals death. 
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Furthermore, we found that the early-death phenotype of these animals was not 
due to melanocyte formation, as mitfa(lf)-mutant animals harboring the CRE and 
Ubiswitch transgenes still experienced an identical pattern of early, fully-
penetrant lethality. We considered the possibility of screening based on the early 
hyper-proliferation of melanocytes seen in larval zebrafish, but the high variability 
of this experimental system would make a large-scale screen challenging. We 
observed that at 4 dpf p53(lf) and Tg(mitfa:CRE)/+; Tg(ubiswitch:NRASQ61K)/+; 
p53(lf) animals had 25.8 ± 3.8 and 51.9 ± 13.4 mean number of 
melanocytes/embryo ± standard deviation in the dorsal head region, respectively. 
This degree of change yields a cohen’s d effect size of 2.65 that would yield a 
statistical power of 0.89 in a two-tailed test with a standard 0.05 probability level 
using at least 8 animals per treatment group. This means that, for our known 
degree of altered melanocyte growth, if we used this model in a large-scale 
screen where we had at least 8 animals per treatment condition, it would yield a 
significant result 88% of the time that a real result should have been observed. 
This power level is above the standard 80% recommended for statistical tests 
and 8-20 embryos per well of a 48-well assay plate has been previously 
recommended for screening zebrafish (196). Despite this reasonable level of 
statistical power possible in our experimental system, it remains to be evaluated 
how well 8+ zebrafish could be maintained in the ~200 ul allowed in a well of a 
48-well plate for the full 4 days required to see our observed phenotype. It is 
possible that larger volumes would be required once fish begin swimming around 
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2 dpf and thus 24-well plates with more volume and perhaps a reduced number 
of fish would be necessary to maintain proper health for 4 days. This represents 
one factor that would reduce the number of chemicals that could be screened 
and increase the amount of each chemical required in the screen. An additional 
difficulty in running this assay would be that it would be necessary to count 
melanocytes, given that the number of melanocytes of roughly 10-20% of 
animals in Tg(mitfa:CRE)/+; Tg(ubiswitch:NRASQ61K)/+; p53(lf) zebrafish 
overlapped with the number of melanocytes in p53(lf) animals, it would difficult to 
accurately score animals as simply transformed or not. Quantification of the 
melanocytes represents a technical hurdle that can be faced since the embryos 
are easily fixed and stored for later counting. This may represent a challenge due 
to the time required to potentially count melanocytes on tens of thousands of 
embryos and automated capillary and image analysis-based techniques could be 
considered for screens of such size. Although the hyper-melanocytic growth 
phenotype does present a potentially screenable phenotype, it remains troubling 
that there is a powerful off-target effect occurring in these fish causing 
melanocyte-independent lethality that may represent too great of a confounding 
factor to further consider this model for screening of melanocyte phenotypes that 
could be affected by the altered physiology of these transgenic animals. 
  
 The development of the Tg(miniCoopR:CRE) stable line presented a new 
option to express CRE and Mitfa at high levels in developing tumors, but these 
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failed to produce a phenotype in larval melanocytes, with median onset of 
pigmented lesion formation occurring around 7 weeks, this animal model also did 
not qualify to be used in a large-scale screening project. Nevertheless, the 
establishment of these animals demonstrated the full recapitulation of zebrafish 
melanocytes with Mitfa expression being driven by the 2.1 kb mitfa promoter, 
which proved to poorly initiate development of larval melanocytes, but adult 
zebrafish were phenotypically normal. With the increased ease of CRISPR-Cas9 
targeting, it may also be possible to develop a CRE-expression line with the CRE 
ORF inserted at the endogenous mitfa promoter to more perfectly capture true 
mitfa expression in early melanocytes. 
 
 This work provides several principles for consideration if future work 
attempts to establish transgenic zebrafish with accelerated tumor onset for 
screening. First, this work could have benefitted from more aggressive 
development of a variety of founder lines to identify those with the most 
functional transgenic gene expression patterns. Each founder line for this project 
only had 2-3 candidate founders that were evaluated, often with 1 being chosen 
quickly on the basis of fluorescence intensity or melanocyte rescue in offspring. 
Perhaps functional validation of additional founders could have identified one 
with better early melanocyte-restricted expression. Next, experiments must 
carefully plan how to establish a connection between the larval phenotype being 
screened and the adult phenotype of interest. In our case we identified early 
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lesion growth that did not relate to the early-death phenotype we observed in 
growing animals, but we did demonstrate that growth of these early lesions 
continuous through development to establish invasive masses of pigment cells. 
Screening for genes or chemicals that affect formation of such early lesions in 
larvae would be anticipated to identify modifiers of tumor development. 
 
Materials and Methods 
DNA vector preparation 
Human BRAFV600E and NRASQ61K ORFs were cloned with the “Ubiswitch” 5’ 
cassette that includes the ubiquitin promoter driving a GFP ORF flanked by LoxP 
sites and a 5’ polyA sequence using Gateway recombination (ThermoFisher) into 
the 395 vector from the Tol2 kit (197).  
Statistical analysis 
Cohen’s d effect size and statistical power for the observed differences in 
melanocyte growth mentioned in the discussion were calculated using the “Effect 
size” and “Statistical power” calculators available at 
www.danielsoper.com/statcalc. 
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